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STELLINGEN 
1. Het verkiezen van de produktie van monoclonale antistoffen boven die van 
polyclonale antistoffen berust vaak meer op gevoelsmatige en markttechni-
sche argumenten dan op wetenschappelijke gronden. 
dit proefschrift 
2. Het succes van de introductie van de melk-progesterontest op de markt is 
niet zozeer afhankelijk van de kwaliteit van de gebruikte monoclonale anti-
stof alswel van de uitvoeringsvorm van de test; een één-stapstest zou recht 
doen aan de mogelijkheden die een dergelijke bepaling biedt. 
dit proefschrift 
3. Absorptie-experimenten, waarin antistoffen tegen het H-Y antigen worden 
uitgeabsorbeerd met suspensies van ^ en ' cellen, tonen aan dat er slechts 
een gradueel verschil in H-Y antigeen expressie is tussen de sexen. 
dit proefschrift 
4. De resorptie van progesteron uit het vetweefsel bij het varken dient nader 
bestudeerd te worden als alternatief voor het algemeen aanvaarde mechanisme 
van compensatoire produktie door de ovaria na het wegvangen van progesteron 
uit de bloedbaan door antistoffen. 
Wang et al., 1984. J.Endocrin. 101:95-100; Cheesman and Chatterton, 
1982. Endocrinology 111:564-571; dit proefschrift 
5. Het niet aantoonbaar voorkomen van een anti-idiotype respons bij herhaalde 
toediening van homologe monoclonale antistoffen bij het rund ondersteunt de 
hapteen-carrier hypothese van Ehrlich et al. (1987). 
Ehrlich et al., 1987. Hybridoma 6:151-160; dit proefschrift 
6. Afhankelijk van het aantal toedieningen, de dosis en de gewenste werkings-
duur dient per toepassing op het gebied van immunomodulatie of immunothéra-
pie een keuze gemaakt te worden tussen homologe of heterologe monoclonale 
antistoffen. 
dit proefschrift 
7. Analoog aan de situatie bij de mens, dient toelating van monoclonale anti-
stoffen voor passieve immunisatie bij landbouwhuisdieren nader geregeld te 
worden op grond van de bepalingen van de diergeneesmiddelenwet; eisen met 
betrekking tot verontreinigingen en toegevoegde stoffen vormen daarbij een 
noodzakelijk onderdeel. 
8. Het onderzoek naar de geslachtsbeïnvloeding van pluimvee in een vroeg sta-
dium van de embryonale ontwikkeling door middel van monoclonale antistof-
fen tegen het H-Y antigeen, bevindt zich in een ethisch spanningsveld van-
wege enerzijds het ingrijpen in het diepste wezen van de natuur en ander-
zijds het alleen al in Nederland "euthaniseren" van 40 miljoen één-dags-
kuikens per jaar. 
9. Popularisering van onderzoekresultaten kan gemakkelijk leiden tot onjuiste 
beeldvorming en zowel onderzoeker als samenleving schade berokkenen. 
10. De visie dat de ontwikkelingen in de biotechnologie deel uitmaken van een 
wetenschap-technologie spiraal waaraan niemand richting geeft, doet tekort 
aan de wetenschappelijke en maatschappelijke verantwoordelijkheid van de 
onderzoeker. 
11. In het wetenschappelijk onderzoek dient voorkomen te worden dat de weten-
schappelijk-technische beheersing van geabstraheerde functies van het dier 
zodanig gaat overheersen, dat het dier zelf in zijn intrinsieke waarde en 
zin niet meer wordt erkend en enkel als produktiemiddel wordt gezien. 
n.a.v. Schuurman, 1989. Het 'technische paradijs', Kok, Kampen 
12. Onverlet het streven naar het bevorderen van het welzijn der dieren, ge-
tuigt onze wetgeving van meer zorg voor dierenleven dan voor ongeboren 
mensenleven. 
13. De snelle vorderingen op het gebied van de anthropogenetica kunnen gemak-
kelijk leiden tot een selectief aborteren van steeds meer ongeborenen met 
een steeds minder ernstige handicap. 
14. In de discussies binnen de thema's van het Conciliair Proces: gerechtig-
heid, vrede en heelheid van de schepping zal scherper moeten worden onder-
scheiden tussen bijbels perspectief, politieke doelstelling en theoreti-
sche analyse, wil het Conciliair Proces tot praktische resultaten kunnen 
leiden. 
15. Wetenschap geeft geen antwoord op de oorsprong en doel van het leven, wel 
op het proces. 
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GENERAL INTRODUCTION 
It has been some fourteen years since the experiments of Köhler and 
Milstein led to the first description of the development of monoclonal 
antibodies. Single molecular species antibodies with desired specificities 
could be produced by the fusion of antibody-producing cells with neoplastic 
cells. The original aims of Köhler and Milstein were to study the range 
of the antibody repertoire and to assess the contribution of somatic muta-
tion to antibody diversity. The potential applications of these single 
monoclonal antibodies were not completely obvious then, but it was clear 
that they would be of significant value. 
In fact, we now look back on the production of monoclonal antibodies 
as a discovery which has led to a vast range of applications, including 
analytical, diagnostic and therapeutic ones, covering the chemical, biolo-
gical and medical sciences. 
The present study aims to describe the potential usefulness of mono-
clonal antibodies in animal production. In Chapter 1 possible applications 
in the areas of diagnostics, passive immunization and fundamental research, 
with emphasis on reproduction, and the inherent limitations of the current 
hybridoma technology as well as the improvements that can be foreseen with-
in the next few years, are discussed. Two examples of the use of monoclonal 
antibodies in diagnostics are extensively studied and highlighted. The 
first one is the production and characterization of monoclonal antibodies 
against progesterone for pregnancy diagnosis in cattle (Chapter 2). The 
second one is the production of antibodies against a male-specific protein, 
the H-Y antigen (Chapter 3). The anti-H-Y antibodies were applied in a 
simple, non-deleterious test for sexing bovine preimplantation embryos 
(Chapter 4). As an example of passive immunization, in Chapter 5 the pos-
sible immunomodulation of steroid plasma levels by anti-progesterone mono-
clonal antibodies in pigs has been described. The observed immunogenicity 
of murine monoclonal antibodies led us to develop a system for the pro-
duction of monoclonal antibodies from domestic species, especially cattle 
(Chapter 6). More insight in the real necessity and the possible advantages 
of the use of homologous antibodies for passive immunization is desirable. 
In that context the availability of both murine and bovine monoclonal anti-
bodies against a common antigen offered us the opportunity to compare the 
efficacy of homologous versus heterologous antibodies when repeatedly ad-
ministered to cattle (Chapter 7). The study is completed with a Summary 
and Final Remarks on some general aspects of the use of monoclonal anti-
bodies in animal production. 
CHAPTER 1 
APPLICATION OF MONOCLONAL ANTIBODIES IN ANIMAL PRODUCTION: A REVIEW 
P. Booman 
Research Institute for Animal Production "Schoonoord", 
P.O. Box 501, 3700 AM Zeist (The Netherlands) 
Published in Livestock Production Science 18 (1988): 199-215 
Reproduced by permission of Elsevier Science Publishers B.V., Amsterdam 
Abstract 
The hybridoma technology for production of monoclonal antibodies cir-
cumvents many of the constraints associated with the use of conventional 
antisera, and consequently broadens the areas of application of antibodies 
in animal sciences. In the present review, the potential usefulness of 
monoclonal antibodies in animal production - with emphasis on reproduction 
- is discussed, including the inherent limitations of the current techno-
logy and the improvements that can be foreseen within the next few years. 
Because of their unique specificity and the fact that they can be produced 
in virtually unlimited quantities, monoclonal antibodies are an important 
tool in diagnostics. However, the use of these antibodies does not always 
guarantee absolute specificity, and the low affinity of many monoclonal 
antibodies will impose a number of limitations on their use. Monoclonal 
antibodies can also be used to optimize physiological processes such as 
growth and reproduction. For this, homologous antibodies will probably 
offer several advantages over their murine counterparts in terms of effec-
tiveness for passive immunization. Some success has already been achieved 
in the development of monoclonal antibodies from livestock species. Final-
ly, it is shown that monoclonal antibodies are becoming extremely powerful 
research tools. 
Introduction 
When an antigen is introduced into an animal, one aspect of the immune 
response is the secretion by plasma cells of antibodies: immunoglobulin 
molecules with binding sites that recognize the shape of particular de-
terminants on the surface of the antigen and bind to them. The combina-
tion of antibody with antigen sets in train processes that can neutralize 
and eliminate the antigen. 
Quite apart from the natural function of antibodies in the immune res-
ponse, they have long been an important tool for investigators, who capita-
lize on their specificity to identify or label particular molecules or 
cells and to separate them from a mixture. However, the heterogeneity of 
the immune response has complicated the use of antibodies as reagents. 
If the antigen is a complex macromolecule, such as a protein, it will con-
tain many antigenic determinants. Each of these antigenic determinants 
may trigger specific B-lymphocytes to differentiate and generate clones 
of plasma cells secreting antibody. Furthermore, a single antigenic deter-
minant can stimulate multiple B-cell clones synthesizing antibodies that 
vary in specificity and affinity. 
Conventional antiserum production 
Immunization with most antigens results in a polyclonal response and 
the accumulation of many different antibodies in the serum. Antisera, 
therefore, may contain immunoglobulins of varying isotypes, affinities, 
specificities and biological activities. The quantity and quality varies 
from animal to animal and even from one bleed to the next in a given ani-
mal. This situation is made more complex if the immunizing agent contains 
minor contaminants of a highly immunogenic nature that are capable of in-
ducing large amounts of an irrelevant antibody. Finally, good antisera 
are usually available in limited amounts, especially if they have been 
raised against weak antigens or if it has been necessary to absorb the 
antiserum to make it specific. Consequently, the production and standardi-
zation of specific immunological reagents is a difficult task. 
Hybridoma technology 
The hybridoma technology developed by Köhler and Milstein (1975) makes 
it possible to overcome these difficulties and, in many cases, to obtain 
a serological reagent that is not only homogeneous and predictable, but 
is also tailormade to the needs of each of the many applications of im-
munological reagents (for a comprehensive review, see Milstein, 1980). 
The basis of hybridoma technology is the immortalization of B-lympho-
cytes with antibody-producing capacities, but limited in vitro growth cha-
racteristics. The lymphocytes are fused with cells from a non-antibody-pro-
ducing and continuously growing tumour cell line or myeloma cell line so 
that hybrids continue to secrete antibodies while gaining the immortality 
of the parent tumour cell. Because each B-lymphocyte produces an immunoglo-
bulin molecule with a fixed specificity, clones derived from hybridized 
cell populations are homogeneous in nature, and each of the clones secretes 
an immunoglobulin with a single molecular structure and antigen specifici-
ty. Thus, all the antibody molecules secreted by the same cell line exhibit 
identical specificity, affinity and isotype (class or subclass). The anti-
bodies produced by the fusion procedure are known as monoclonal antibo-
dies, distinguishing them from the heterogeneous polyclonal antibodies 
obtained by conventional antibody production. Antibody-producing clones 
may be stored in liquid nitrogen in the viable state and retrieved at will 
for culture and production of the corresponding antibody. In Fig. 1, a 
comparison is made between the monoclonal antibody technique and the con-
ventional technique to prepare antibodies. 
There is a number of excellent books and reviews dealing with the spe-
cific details of monoclonal antibody production techniques (Goding, 1980, 
1983; Galfrè and Milstein, 1981; Campbell, 1984). The benefits of mono-
clonal antibodies have resulted in the hybridoma technology being applied 
to many basic and practical problems. In animal production, monoclonal 
antibodies are increasingly finding application in the areas of diagnos-
tics, passive immunization and fundamental research. In the following sec-
tions, some applications of monoclonal antibodies within these areas with 
emphasis on reproduction are discussed. A complete review is beyond the 
scope of this article. The aim is to describe critically the potential 
usefulness of monoclonal antibodies in animal production, the inherent 
limitations of the current hybridoma technology and the improvements that 
can be foreseen within the next few years. 
Monoclonal antibodies versus polyclonal antibodies 
It is evident that monoclonal antibodies have some major advantages 
over conventional polyclonal antisera. Firstly, monoclonal antibodies are 
homogeneous and permanently-available reagents that can be obtained in 
large amounts. Another major advantage is that pure antibodies can be ob-
tained even when impure antigens were used to immunize. This is important 
because many biologically-significant antigens have not been purified to 
homogeneity. It is even possible to use the hybridoma technology to look 
for antigens whose existence is only suspected, and whose structure and 
properties are completely unknown. In addition to these obvious benefits, 
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Fig. 1. Immune response is initiated (a) when an antigen molecule carrying 
several different antigenic determinants enters the body of an animal. \ 
The immune system responds: lines of B-lymphocytes proliferate, each secre-
ting an immunoglobulin molecule that fits a single antigenic determinant 
(or a part of it). A conventional antiserum contains a mixture of these 
antibodies. Monoclonal antibodies are derived by fusing lymphocytes from 
the spleen with malignant myeloma cells (b). Individual hybrid cells are 
cloned, and each of the clones secretes a monoclonal antibody that specifi-
cally fits a single antigenic determinant on the antigen molecule 
(Milstein, 1980). 
hybridoma technology makes it possible to generate a battery of monoclonal 
antibodies that react with a particular antigen and to select those anti-
bodies that will be best for a particular task. Individual monoclonal anti-
bodies can be chosen on the basis of their affinity, specificity or iso-
type. 
Despite the great potential of monoclonal antibodies, there are several 
disadvantages to their use that deserve consideration. Since a monoclonal 
antibody detects a single antigenic determinant it may be more influenced 
by conditions that alter the binding properties of the single binding site, 
and in addition it will not form the lattice-like antigen-antibody struc-
ture required for direct precipitation, unless the antigen has more than 
one identical antigenic determinant (i.e., polyvalent antigen) distributed 
in a favourable conformation. The utility of otherwise valuable monoclonal 
antibodies may also be limited by the fact that the antibodies are of a 
specific subclass and, therefore, restricted to the functions that can 
be carried out by antibodies of that class. Such limitations may be minor 
and can often be circumvented, but must be taken into consideration when 
these reagents are used instead of polyclonal antisera. 
Diagnostics 
Monoclonal antibodies in diagnostics 
Several recent reviews (Scott, 1985; Sevier, 1985) have expressed the 
belief that monoclonal antibodies will soon replace polyclonal antisera 
as standard reagents for immunological assays. However, the time and effort 
required to obtain monoclonal antibodies with suitable properties is con-
siderable. Furthermore, for those assays which already operate satisfac-
torily with adequate supplies of conventional antiserum there may be little 
to be gained by production of a monoclonal antibody. 
The properties of monoclonal antibodies mean that they are very valuable 
diagnostic tools in certain situations. Firstly, it is possible to pro-
duce specific antibodies from impure material. Secondly, for different 
antigens which possess common structural features, antibodies can be ob-
tained which are directed against structures unique to a particular antigen 
and are, therefore, totally specific. Finally, the capacity to produce 
monoclonal antibodies in large quantities and with constant characteristics 
is valuable for assays demanding substantial amounts of antibody and for 
standardizing immunological assays. 
Pregnancy diagnosis 
An example of a typical diagnostic test in animal production in which 
monoclonal antibodies might be used is the milk-progesterone test for con-
firmation of oestrus and pregnancy diagnosis in cattle (Robertson and 
Sarda, 1971; Heap et al., 1973). The progesterone concentration in either 
blood plasma or in milk at oestrus is very low and rapidly rises to a high 
level at mid-cycle. This level is maintained throughout pregnancy. If a 
cow does not become pregnant, the progesterone level falls around Day 16-
19 after last oestrus. Several enzyme immunoassays for the determination 
of progesterone have been described in the literature, most of them employ-
ing polyclonal antibodies (Arnstadt and Cleere, 1981; Van de Wiel and 
Koops, 1986). However, for commercialization, the milk-progesterone test 
has to be standardized and in that case monoclonal antibodies are the pre-
ferred reagents. Several groups have prepared monoclonal antibodies to 
progesterone (Fantl et al., 1982; White et al., 1982; Booman et al., 
1984a). These antibodies differed considerably in their specificity and 
affinity for progesterone. The best monoclonal did not detect progesterone 
with any greater sensitivity than the conventional polyclonal sera. How-
ever, the use of monoclonal antibodies leads to improvements in test stan-
dardization and avoids the dependency upon animals producing high quality 
antisera. ImmuCell Inc. (U.S.A.) has designed a rapid progesterone cow-
side test based on the antibody with the best characteristics produced 
in our laboratory. This test can be performed by the farmer himself and 
the results are known within 4 min. 
In pigs, increased levels of oestrone sulphate in plasma have been de-
monstrated early in pregnancy from Day 16 with a maximum on Day 40 
(Robertson and King, 1974). A pregnancy diagnosis test can be based on 
the differences in plasma levels between pregnant and cyclic pigs (Guthrie 
and Deaver, 1979; Edqvist et al., 1980). Besides standardization of a kit 
for pregnancy diagnosis, monoclonal antibodies have the advantage that 
they can specifically bind with oestrone sulphate whereas polyclonal anti-
bodies are mostly directed against oestrone. The necessity for hydrolysis 
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of oestrone sulphate can, therefore, be avoided. At our laboratory very 
specific and high affinity monoclonal antibodies have been prepared for 
oestrone and oestrone sulphate, respectively. 
A similar application of monoclonal antibodies is their use in rapid 
solid phase sandwich enzyme immunoassays to measure equine and bovine lu-
teinizing hormone for detection of ovulation and equine pregnant mare serum 
gonadotrophin (PMSG) for pregnancy diagnosis (Kasper et al., 1985a,b; Roser 
et al., 1985). These monoclonal antibodies could be useful in manufacturing 
test kits for field applications demanding substantial amounts of antibody. 
Sexing embryos and sperm 
Another application in animal reproduction is the use of monoclonal 
antibodies against the H-Y antigen for sexing bovine embryos before trans-
plantation (for a review, see Booman, 1986). The H-Y antigen is a histocom-
patibility antigen, detected in 1955 by Eichwald and Silmser, and present 
on the surface of male cells, but not on those of the female (Billingham 
and Silvers, 1960). Because of the exclusive presence of the H-Y antigen 
in the mammalian male (Wachtel et al., 1975) and its detection early in 
embryonic development (Krco and Goldberg, 1976), it has become possible 
to predict the phenotypic sex of the offspring on the basis of embryonic 
H-Y antigen expression. Polyclonal antibodies against the H-Y antigen can 
be raised by injecting female C57B1/6 mice with cells of males of the same 
inbred strain. Anti-H-Y antibodies of the mouse have been used to identify 
XY cells in some 70 species from all classes of vertebrates (for referen-
ces, see Wachtel, 1983). The antigen appears to lack species specificity 
and, therefore, the antibodies can be used to identify bovine embryos. 
The H-Y antigen is a weak antigen and immunization with H-Y antigen usually 
results in production of low titer, low affinity antisera. Because only 
a low percentage of mice have a good antibody response and their sera run 
out quickly, it would be preferable to have monoclonal antibodies. Several 
monoclonal antibodies have already been developed (Koo et al., 1981; Farber 
et al., 1982; Shapiro and Goldberg, 1984). However, the affinity of all 
these monoclonal antibodies appears to be low. In our laboratory we have 
been trying to produce specific, high affinity monoclonal antibodies 
against the H-Y antigen (Booman et al., 1988a). Evaluation of bovine em-
bryos for expression of H-Y antigen using these monoclonal antibodies in 
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an indirect immunofluorescence assay has been shown to be reasonably accu-
rate. The assessment of fluorescence, however, is highly subjective. Work 
must still be done to modify the procedure in such a way that subjectivity 
is reduced. 
It is unlikely that monoclonal antibodies against the H-Y antigen can 
be used as a means for the selection of X or Y chromosome-bearing sperm. 
Success would depend on haploid expression of H-Y antigen by Y-bearing 
spermatozoa. It is clear, however, that expression of the H-Y antigen re-
quires the Y-linked gene as well as an X-linked one (Ohno, 1979; Wachtel 
and Ohno, 1980). Ohno (1982) supposed that the H-Y antigen present in abun-
dance on the sperm plasma membrane is actually contributed by Sertoli cells 
and not synthesized by germ cells with a dormant X chromosome, the implica-
tion of which is that spermatozoa passively become H-Y positive regardless 
of sex chromosomal type. 
Other diagnostic applications 
A .valuable in vitro diagnostic assay might be to evaluate whether sperm 
has been capacitated or not. Capacitation is the alteration of factors 
on the sperm cells necessary for fertilization (for a review, see Bedford, 
1983). Monoclonal antibodies specific for appropriate surface antigens 
may give information about changes in surface organization that appear 
to accompany capacitation (Saxena et al., 1986). Preservation of boar semen 
during several days in appropriate buffer may not induce capacitation; 
on the other hand, for in vitro fertilization purposes capacitated sperm 
is a prerequisite. Such antibodies require a high degree of specificity. 
Specificity is also of importance in the production of blood-typing 
reagents for farm animals. Blood group antigens have been widely used in 
the genetic identification of livestock, and the antigens of the major 
histocompatibility complex hold promise as markers for immune response 
genes in domestic species. Monoclonal antibodies would increase the ef-
ficiency of routine blood typing and allow for international standardi-
zation of genetic markers of many types (Tucker et al., 1981). 
Another potentially valuable application is in the area of food ana-
lysis, such as the identification of the species origin of meat products 
and the determination of residues of hormones or growth promotors in milk 
and meat (for references, see Morris and Clifford, 1985). Monoclonal anti-
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bodies would improve the accuracy and reproducibility of the results from 
immunoassay techniques and offer a cheap standardized method of screen-
ing a large number of samples rapidly and accurately. 
Specificity and affinity of monoclonal antibodies 
Two remarks should be made concerning the use of monoclonal antibodies 
in diagnostics. In polyclonal antisera where antibodies are derived from 
multiple distinct B-cell clones, cross-reactivity is a major problem. Al-
though the technique of monoclonal antibody production selects for an anti-
body with specificity for a single antigenic determinant, this does not 
always preclude the presence of cross-reactivity. The specificity of an 
antibody is a quantitative phenomenon that is determined by its affinity 
for a defined antigenic structure as compared to other antigens. It is 
clear that the discriminating abilities of monoclonal antibodies are poten-
tially very great, although impossible to predict in advance. The ability 
to obtain highly-specific antibodies obviously depends on the existence 
of structural features unique to a given molecule, and on the maximum affi-
nity differences likely to be possible to allow binding to these, but not 
to modified determinants on other molecules. It is also necessary that 
such structural features make a significant contribution to the overall 
immunogenicity of the molecule, although even in this case it is a matter 
of generating enough monoclonal antibodies to find the right one. 
In addition, most antibodies derived by hybridoma technology have af-
finities far below the corresponding conventional antisera. In a polyclonal 
antiserum, the majority of antibodies will also have low affinities, but 
the few high affinity antibodies will dominate the reaction and provide 
the necessary sensitivity. However, a monoclonal antibody can exhibit an 
affinity anywhere within the full range and one must identify those few 
of sufficient affinity. Some recent evidence has suggested that the high 
affinity of polyclonal relative to monoclonal antibodies may reflect more 
than a simple statistical incidence of different individual affinities 
in a large population. Some mixtures of 2 monoclonal antibodies for dif-
ferent antigenic determinants on a given antigen show cooperativity in 
that the affinity of the mixture is considerably higher than that of the 
individual antibodies (Ehrlich et al., 1983). If high affinity monoclonal 
antibodies are of particular importance, the screening assays for selecting 
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relevant antibodies must be designed to exclude low affinity antibodies. 
All things considered, it is always necessary to evaluate carefully the 
need of making monoclonal instead of polyclonal antibodies for a given 
antigen as considerable time and effort is required to obtain monoclonal 
antibodies with suitable properties. 
Passive immunization 
Immunoneutralization by active and passive immunization 
Immunization against biologically active substances, such as hormones, 
can produce a wide variety of effects, including neutralization of the 
selected substance, blocking of action or even enhancement of action of 
a substance. The nature of these effects will be influenced by level, spe-
cificity and affinity of the antibodies, regardless of whether they are 
a result of active or of passive immunization. 
It has been hypothesized (Cox et al., 1985) that in the neutralization 
of selected substances (the system that is most commonly considered), the 
active substance is bound to antibody and hence becomes biologically un-
available. In this way, there is a direct reduction of biological mate-
rial available for target tissues. Many other, secondary, effects may be 
a consequence of the immunization, e.g., disturbance of a metabolic network 
and quantitative alteration in other active substances. There are now many 
examples showing the physiological effects of immunizing animals against 
hormones; for instance, immunization of sheep to gonadal steroids during 
the breeding season may raise the ovulation rate (Pathiraja, 1982) resul-
ting in an increased number of lambs born (Land et al., 1982). A possible 
mechanism that can explain such an effect is that the antisera interfere 
with the equilibria between gonadotrophin release and gonadal activity 
(Land et al., 1983). Immunization against luteinizing hormone-releasing 
hormone can produce immunocastration and meat quality changes in rams and 
bulls (Schanbacher, 1982; Robertson et al., 1982); somatostatin immunity 
has been reported to bring about growth changes (Spencer et al., 1983) 
and immunization against inhibin results in early onset of puberty as well 
as increased ovulation rate in sheep (O'Shea et al., 1982; Henderson et 
al., 1984). 
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Alternatively, there is a possibility that antibodies could be used 
effectively to bind to receptors and hence to block hormones from reaching 
the receptors, thus resulting in modification of hormone action. 
Enhancement of action of a substance by immunization has hardly been 
explored, but may have very useful applications. Such effects were noted 
by Holder et al. (1985), who showed that the binding of a monoclonal anti-
body to human growth hormone resulted in marked enhancement of the somato-
genic activity of the hormone in vivo. The same group found that the bind-
ing of some monoclonal antibodies to bovine growth hormone also resulted 
in enhancement of biological activity and that the effect was dependent 
on the binding site specificity of the monoclonal antibody (Aston et al., 
1987). The mechanisms behind this phenomenon are not clear. 
Immunoneutralization by active immunization is not a reproducible ef-
fect. Within species, and even within breeds, there can be marked varia-
tions in the magnitude and speed of antibody response. The effect of active 
immunization is manifested only in those animals which form adequate titers 
of antibodies. The effects could be brought about in a repeatable manner 
by passive administration of preformed antibodies. Also, in contrast to 
the slow acquisition of antibody titer following active immunization, pas-
sive immunization results in an immediate neutralization. The ability to 
immediately and specifically neutralize hormone activity provides a means 
of influencing a physiological process at a very precise moment. A good 
example of this is the administration of (polyclonal) antibodies against 
pregnant mare serum gonadotrophin (PMSG) in superovulated cattle immediate-
ly after insemination, where the surplus of PMSG is neutralized and conse-
quently the number of embryos of good quality can increase (Bouters et 
al., 1983). Finally, passive immunization has proved useful in the treat-
ment of certain animal diseases where prophylactic measures are not pos-
sible. However, the amounts of antisera required for passive immunization 
are very large, so that with polyclonal antibodies it is possible to treat 
only a restricted number of animals. The hybridoma technique offers the 
possibility of obtaining antibodies of the required specificity and charac-
teristics in unlimited amounts. 
The first commercial application of monoclonal antibody administration 
in vivo was to protect neonatal calves against diarrhoea caused by ente-
rotoxigenic Escherichia coli. Oral administration of monoclonal antibodies 
specific for the K99 pilus antigen of E. coli passively protects animals 
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in laboratory and field conditions (Sherman et al., 1983). Recently, a 
commercial preparation of monoclonal antibodies has been introduced against 
PMSG to improve the results of superovulation in cattle (Dieleman et al., 
1988). Other applications will certainly follow. 
Limiting factors of monoclonal antibodies in passive immunization 
It will, however, take some time for the potential of monoclonal anti-
bodies to be fully realized in animal production. In spite of new mass 
culture techniques, the production costs of purified monoclonal antibodies 
are still high so that not all applications are yet economically attrac-
tive. Another limitation may be the reaction of the treated animal to the 
effects of passive immunization. For instance, in the case of anti-steroid 
antibodies, the animal may restore its hormone level via compensatory pro-
duction, shifting of equilibria in the steroid pathway and release of ste-
roids from fat deposits (Booman et al., 1984b; Wang et al., 1984). A third 
limitation might be the murine or rat origin of monoclonal antibodies when 
applied in other species. Once these antibodies have been recognized as 
foreign, an anti-mouse immunoglobulin response may develop which limits 
the further effectiveness of the monoclonal antibody. In addition, hetero-
logous antibodies may not elicit cooperative cellular effects. As reported 
by Nose and Wigzell (1983) and reviewed by Larrick and Buck (1984), anti-
bodies have species-specific carbohydrates which are important in several 
antibody effector functions. 
Despite these drawbacks, murine monoclonal antibodies have been used 
succesfully to neutralize PMSG in superovulated cattle (Dieleman et al., 
1988). It is not yet known, however, whether repeated injections given 
over a period of time remain effective. In pigs, repeated administration 
of murine antibodies generated a significant antibody response to mouse 
immunoglobulins (Arriëns and Booman, 1988). Human clinical trials with 
murine monoclonal antibodies indicate that almost all non-immunocompro-
mised patients developed anti-mouse immunoglobulin antibodies which neu-
tralized the therapeutic effect (for references, see Cole et al., 1985). 
The neutralizing effect of human anti-mouse antibody is due to a host im-
mune response against both the constant portions of the mouse immunoglobu-
lin molecule and the variable region (idiotype) reacting with the antigenic 
determinant (Levy et al., 1984). 
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These findings have important implications for the eventual use of homo-
logous monoclonal antibodies for passive immunization. Such antibodies 
may likewise evoke an anti-idiotypic immune response. However, Ehrlich 
et al. (1987) reported that only one out of five rhesus monkeys injected 
repeatedly with human monoclonal antibodies produced anti-idiotypic anti-
bodies. They suggested that the anti-idiotypic antibodies that are preva-
lent in the human anti-mouse monoclonal antibody response are elicited 
through a hapten-like effect, in which the heterologous immunoglobulin 
acts as a carrier for the idiotype. 
Production of homologous antibodies 
Although anti-idiotypic responses cannot be excluded as a complicating 
factor, homologous antibodies will probably offer several advantages over 
their murine counterparts in terms of effectiveness for passive immuniza-
tion. Unfortunately, the production of, for instance, bovine or porcine 
monoclonal antibodies has been greatly hampered by the lack of myeloma 
fusion partners for lymphocytes from these species. 
Nevertheless, some success has already been achieved in the develop-
ment of monoclonal antibodies from livestock species. Srikumaran et al. 
(1983) demonstrated the potential of interspecies hybridomas, produced 
by fusing mouse myeloma cells with bovine lymphocytes. This strategy cir-
cumvents the necessity of developing homologous fusion partners. More re-
cently, the generation from such interspecies fusions of bovine antibodies 
with specificity for bovine enteric coronavirus (Raybould et al., 1985) 
as well as antigen-specific ovine monoclonal antibodies has been reported 
(Beh et al., 1986; Groves et al., 1987). A severe limitation to interspe-
cies hybridomas, however, is their genetic instability, due to the selec-
tive elimination of the non-murine chromosomes. 
In another approach, mouse x bovine hybrid myelomas (heteromyelomas) 
have been constructed in attempts to obtain a better fusion partner for 
the production of bovine monoclonal antibodies (Tucker et al., 1984; Booman 
et al., 1988b). It was anticipated that a heteromyeloma would retain the 
superior fusion characteristics of the mouse myeloma cells and be better 
able to support stable bovine antibody production because of the presence 
of bovine chromosomes. With these heteromyeloma cell lines bovine anti-
bodies have been produced against the Forssman antigen (Tucker et al., 
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1984) and at our laboratory against rotavirus and PMSG. Current research 
is focused on the effectiveness of murine monoclonal antibodies compared 
to bovine antibodies against PMSG in superovulated cattle after repeated 
treatments. 
Fundamental research 
The potential of monoclonal antibodies as research tools is clearly 
enormous. This is due to the specificity of monoclonal antibodies which 
allows discrimination between closely related antigenic determinants. 
One of the areas where monoclonal antibody technology is having a major 
impact is in analysis of the mechanism of immune regulation and delineation 
of the genetic basis of disease susceptibility. The use of monoclonal anti-
bodies has permitted the development of precise immunological reagents 
that can be used to define the network of functional subpopulations of 
lymphoid cells in livestock species and the antigens of the major histocom-
patibility complex that are centrally involved in the regulation and ex-
pression of the immune response (for references, see Davis et al., 1985). 
Monoclonal antibodies can be applied to define the functional roles of 
sperm constituents during differentiation and fertilization and to identify 
and resolve the functions of many regulatory substances with crucial roles 
in mammalian gametogenesis, fertilization and development (for references, 
see Bellvé and Moss, 1983). A further consequence of the fact that one 
particular monoclonal antibody recognizes only one antigenic determinant 
of an antigen is that monoclonal antibodies may be useful reagents in mole-
cular studies of receptor structure and function (Greene et al., 1980) 
or in studying the orientation of hormones when bound to their receptors 
(Moyle et al., 1982). 
Monoclonal antibodies can also be used effectively as biochemical rea-
gents for the affinity purification of antigenic molecules of interest 
in animal production. The affinity of monoclonal antibodies is frequently 
reported as being low relative to their polyclonal counterparts. Low affi-
nity antibodies are generally more suitable than high affinity antibodies 
for use in immunopurification schemes (Morgan et al., 1984), because of 
the relative ease of elution of antigen in an active form. 
A novel and useful application of monoclonal antibodies is in the devel-
18 
opraent of anti-idiotypic antibodies. The binding site on the monoclonal 
antibody, the idiotype, consists of a region complementary to the antigenic 
determinant. The production of antibodies directed against another antibody 
molecule will result in some antibodies specific for the idiotypic region, 
the so-called anti-idiotypic antibodies (Marx, 1985). The binding region 
of the anti-idiotypic antibody mimics the architectural configuration of 
the original antigenic determinant. The mimicry is so accurate that in 
some cases the anti-idiotypic antibody may be utilized instead of antigen 
for the identification or induction of antibody. It has been suggested 
by Kelley and Lewin (1986) that this approach could be particularly useful 
in vaccine production for antigen preparations that might remain infectious 
after isolation, or for those antigens that are difficult to isolate and 
to characterize. Anti-idiotypic antibodies might also be used as a tool 
to mimic the antigen in vitro (e.g., diagnostic assays) or in vivo (e.g., 
to mimic insulin and cause glucose entry into a cell). 
These examples are only intended to give an impression of the many pos-
sible uses of monoclonal antibodies in fundamental research and thus to 
show what a valuable instrument has been made available to animal sciences. 
Conclusions 
The particular advantages of monoclonal antibodies can be first and 
most easily shown in immunodiagnosis. Once a hybridoma producing a mono-
clonal antibody appropriate for a particular task has been obtained, large 
amounts of a homogeneous and reliable reagent are available for as long 
as they are needed. Monoclonal antibodies may also prove to be important 
in passive immunization, although such applications require more basic 
research. The advent of better methods for producing antibodies from live-
stock species may increase the versatility of this technology. Finally, 
it is evident that monoclonal antibodies are becoming extremely powerful 
research tools. There is no doubt that the monoclonal antibody technology 
will have an important impact on the improvement of animal quality and 
productivity. 
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Abstract 
In order to standardize an enzyme immunoassay of milk-progesterone as 
a routine method for early pregnancy diagnosis in cattle, several mono-
clonal antibodies against progesterone were produced. The antibodies dif-
fered considerably in their binding affinity for progesterone and showed 
distinct specificities for a variety of steroids. However, the antibody 
with the highest association constant for progesterone (K^ = 2 x 10 
1/mol) also showed good specificity. Using this antibody in a direct double 
antibody solid phase enzyme immunoassay (EIA), the detection limit of the 
assay was 1 pg, whereas a 50% reduction of maximum binding in the standard 
curve was obtained by addition of 18 pg of progesterone. The titer (= work-
ing dilution in the EIA-system) of ascites fluid of this IgM antibody was 
1:13,500,000, and of cell culture medium 1:12,000. 
Introduction 
The day-to-day variations in plasma progesterone in non-pregnant cows 
display a cyclic pattern, which is characterized by minimal plasma pro-
gesterone levels from two days before to three days after ovulation, a 
sharp rise from Day 5 to Day 7 of the cycle, and a very slow rise or pla-
teau on the subsequent eight to ten days. 
An important feature of the bovine cycle is the abrupt fall in peri-
pheral plasma progesterone levels which occurs between the third and second 
day before oestrus. Since this fall is not seen in pregnant animals, an 
early pregnancy diagnosis can be made at 3 weeks after insemination by 
determination of progesterone levels in plasma or milk. Progesterone levels 
in milk accurately reflect the concentration in plasma. It is preferable 
to measure progesterone in milk because milk samples can be easily collec-
ted. Application of the milk-progesterone test for the purpose of early 
pregnancy diagnosis can be of great importance to the modern dairy far-
mer with a large herd and a tight calving pattern, where the optimum cal-
ving interval has a pronounced financial impact. 
For the direct measurement of progesterone in milk and plasma, a sen-
sitive and simple enzyme immunoassay (EIA) has been developed by Van de 
Wiel and Koops (1). Routine application of the test in practice and on 
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a large scale demands substantial amounts of antibody. Unlimited quantities 
of identical antibodies, which will allow standardization of the assay 
within and between laboratories, can be produced by the technique of soma-
tic cell fusion according to Köhler and Milstein (2). Improvement in assay 
sensitivity and specificity can be obtained by screening a number of cell 
lines for the production of monoclonal antibodies with desired characteris-
tics. In this paper we describe the production of monoclonal antibodies 
to progesterone by the hybridoma technique, and the use of one of these 
antibodies for the measurement of progesterone by EIA. 
Materials and Methods 
Production of hybridomas 
Hybridoma cell lines were produced according to techniques initially 
developed by Köhler and Milstein (2). 6-8 Week old male Balb/c mice were 
injected intraperitoneally with either lla-hydroxyprogesterone-hemisucci-
nate conjugated to bovine serum albumin (P-lla-BSA), or progesterone-7a-
carboxyethylthioether conjugated to bovine thyroid globulin (P-7a-BTG). 
100 fig of each conjugate had been dissolved in phosphate buffered saline 
(PBS) and emulsified with complete Freund's adjuvant (1:1). A second in-
jection was given three weeks later in exactly the same way as above, ex-
cept that incomplete Freund's adjuvant was used. Finally, 6-10 weeks after 
the last inoculation and four days before collection of the spleen cells, 
the animals were boosted intravenously with 50 /ig of antigen in 0.1 ml 
PBS. 
Spleen cells were isolated for fusion and erythrocytes were lysed by 
incubation with 0.83% (w/v) NH4CI for 1 min at room temperature (rT). The 
X63-Ag8.653 mouse myeloma cell line (3) was maintained in Dulbecco's Modi-
fied Eagle's Medium (DMEM) supplemented with 15% heat-inactivated fetal 
calf serum (FCS)(DMEM-15), penicillin, streptomycin and glutamin. 
For each fusion a mixture of 10 spleen cells and 2.5 x 10' myeloma 
cells was washed three times in DMEM. The pellet was resuspended in 1 ml 
of 50% (w/v) polyethylene glycol 4000 in DMEM containing 10% dimethylsulf-
oxide. The suspension was incubated for 1 min at rT and subsequently di-
luted stepwise over a period of 6 min with 8 ml DMEM. Then 6 ml DMEM-15 
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were added and the suspension was pipetted up and down gently and centri-
fuged for 7 min at 800 rpm. The pellet was resuspended in 150 ml DMEM-15 
and the cells were distributed over six 384-well Greiner TC cloning plates 
and incubated at 37°C in a humidified C02"incubator (7.5% CO2) for 24 h, 
with 5 x 10 mouse macrophages per ml as feeder cells. The cultures were 
then supplemented with an equal volume of DMEM-15 containing hypoxanthine, 
aminopterin and thymidine (HAT). Medium was refreshed every 3-4 days for 
2 weeks with HAT medium with decreasing concentrations of FCS. Then the 
culture medium was exchanged for DMEM containing hypoxanthine and thymidine 
only. Selected antibody-producing clones were passaged onto tissue culture 
flasks and split for storage in liquid nitrogen. Cloning of the hybrid 
cells was done by limiting dilution in 96-well plates in a feeder cell 
culture-conditioned medium. 
For production of ascites fluid, Balb/c mice were injected intraperi-
toneally with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane). After 
1-3 weeks the mice were inoculated with 2.5 x 10 hybridoma cells. About 
0.5 ml of serum and 2-8 ml of ascites fluid were obtained from individual 
animals between 1 and 3 weeks later. 
Detection of antibody production 
Hybridoma supernatants and ascites fluids were screened for the pre-
sence of anti-progesterone antibody in a double antibody solid phase EIA. 
The Ig fraction of a rabbit antiserum against mouse immunoglobulins was 
isolated by Na2S04 precipitation and was used for coating (18 h at 4°C) 
of polystyrene microtiter plates (10 fig Ig/ml, 100 /il/well) at pH 9.6 in 
0.05M NaHC03 buffer. A second coating (50 min at rT) was done with 1% BSA 
to prevent non-specific binding effects. The plates were washed, dried, 
sealed and stored at 4°C until use. Subsequently the plates were incubated 
(2 h at rT) with 100 fil hybridoma supernatant or ascites fluid diluted 
in 0.04M PBS pH 7.2 containing 0.1% BSA. The supernatants were aspirated 
and the plates were washed five times with 0.05% Tween 80. Synthesis of 
the conjugates was performed according to the modified mixed anhydride 
method of Dawson et al. (4). Horse-radish peroxidase was conjugated to 
either 6y8-hydroxyprogesterone-hemisuccinate, 7a-hydroxyprogesterone-car-
boxyethylthioether or lla-hydroxyprogesterone-hemisuccinate (P-6-HRP, P-
7-HRP and P-ll-HRP, respectively). P-HRP was added (5 ng/well) and the 
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plates were incubated for 2 h at rT in the dark. The reaction was stopped 
by aspiration of the supernatants and the wells were washed five times 
with 0.05% Tween 80. Substrate solution was prepared in 0.IM acetate-ci-
trate buffer pH 5.5 and contained tetramethylbenzidine in dimethylsulfoxide 
(0.0075%) and H2O2 (0.004%). 150 pi of substrate solution was added to 
the wells of the plates. After an incubation period of 45 min at rT, the 
reaction was stopped with 50 pi 4N H2SO4. The absorbance was read at 450 
nm with a spectrophotometer (Titertek multiskan). 
Characterization of antibodies 
The specificity and the affinity of the various monoclonal antibodies 
in the supernatants of the cell cultures were determined according to 
Abraham (5) and Scatchard (6), respectively. The assays were performed 
as described for the screening system of antibody production by the hy-
brid clones. The titer of the antibodies was defined as the dilution of 
cell culture supernatant or ascites fluid which resulted in half of the 
maximum binding of 5 ng of tracer. 
Immunoglobulin (sub)class was determined by the double diffusion me-
thod of Ouchterlony. Anti-mouse immunoglobulins were obtained from Miles 
Laboratories. 
Results and Discussion 
Production of hybridomas 
Fusion of spleen cells from immunized mice with the mouse myeloma cells 
resulted in the growth of hybrid cells in about 60% of the wells of the 
TC cloning plates. After two weeks of growth specific antibody-secreting 
cells were detected by EIA in about 10% of the wells with hybrid clones. 
Although the cells were cloned as soon as possible, more than half of the 
positive hybridomas lost their ability to secrete antibodies during subse-
quent cell culture. Two cell fusions with P-lla-BSA as immunogen and three 
cell fusions with P-7a-BTG as immunogen ultimately resulted in 6 and 8 
stable cell lines, respectively. No significant difference in the frequency 
of hybridomas was observed between the fusing experiments with the two 
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different antigens. 
Characterization of monoclonal antibodies 
Specificity and affinity of the monoclonal antibodies, as determined 
according to Abraham (5) and Scatchard (6) respectively, are shown in Table 
1A and IB. 
The cross-reactivity of the antibodies produced by the different cell 
lines varied widely. The high degree of cross-reactivity with lla-hydroxy-
progesterone and 11/3-hydroxyprogesterone for antibodies raised against 
the lla-hydroxyprogesterone conjugate was not unexpected. The highest 
cross-reactivity with 11/8-hydroxyprogesterone (24,194%) was observed in 
cell line lab4, which had a very low affinity for progesterone (K^ = 2 
x 10' 1/mol) and a poor specificity. Most antibodies showed remarkably 
high cross-reactivity with pregnanedione, 11-ketoprogesterone, 5-pregnene-
3/3,20a-diol and, except for the cell lines lab4, 2VIII and 711, with 5a-
pregnane-3,20-dione. Some antibodies bound to these steroids with compara-
ble or even higher affinity than to the homologous steroid hapten. In gene-
ral, antibodies raised against the progesterone-7a-carboxyethylthioether 
antigen did not show better specificity than those raised against the 11a-
hydroxyprogesterone-hemisuccinate antigen, regardless of whether they were 
tested in a homologous or in a heterologous system. This indicates that 
specificity could not be improved by site heterology (variation in the 
site of attachment of the hapten to the macromolecular carrier in the immu-
nogen). Furthermore, when antibody 4XVIII was incubated with the hetero-
logous tracer P-7-HRP, it appeared that the degree of cross-reactivity 
with nearly all steroids tested increased compared to incubation with the 
homologous tracer (P-ll-HRP). This effect of heterology is in agreement 
with previous observations reported by Bosch and Schuurs (7). It was sur-
prising, however, that binding did indeed occur. In fact, binding was not 
expected at all, because the sites of attachment of progesterone on the 
antigen (11-position) and on the tracer (7-position) were just opposite 
to each other, which theoretically might lead to maximum steric hindrance. 
All other antibodies did only bind to the homologous or nearby homologous 
tracer. 
Association constants (K^) of all monoclonal antibodies for their homo-
logous tracers were rather low. However, when tested with the heterologous 
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TABLE IA 
Characteristics of monoclonal antibodies raised against lla-hydroxyprogesterone-hemisuccinate conjugated 
to bovine serum albumin (P-11a-BSA). 
Tracer (P-6/7/11-HRP) 
Steroid 
progesterone 
1la-hydroxyprogesterone 
11B-hydroxyprogesterone 
16a-hydroxyprogesterone 
17a-hydroxyprogesterone 
20a-hydroxyprogesterone 
20ß-hydroxyprogesterone 
5a-pregnane-3,20-dione 
pregnanedione 
pregnenolone 
17a-hydroxypregnenolone 
5ß-pregnane-3a,20ß-diol 
pregnanetriol 
11-ketoprogesterone 
5-pregnene-38,20a-di ol 
58-pregnane-3a,17a, 
21-triol-20-one 
1,4-diene-7a,21-diol-
3,20-dione 
ethiocholanolone 
etiocholan-3,17-dione 
cholesterol 
Cortisol 
cortisone 
corticosterone 
desoxycorticosterone 
aldosterone 
testosterone 
5a-dihydrotestosterone 
5B-dihydrotestosterone 
epitestosterone 
17B-oestradiol 
oestrone 
oestriol 
androsterone 
androstenedione 
androstenone 
Affinity constant (109 1/mol 
Immunoglobulin class 
Vb7 
11 
100 
34 
7.1 
2.0 
4.4 
0.3 
0.5 
26 
174 
3.7 
< 0.01 
0.08 
0.06 
28 
122 
0.8 
0.4 
71 
9.8 
< 0.01 
0.2 
0.6 
1.5 
2.8 
0.1 
1.4 
1.2 
5.4 
0.5 
< 0.01 
0.05 
< 0.01 
4.7 
0.9 
< 0.01 
0.2 
I9G, 
Vb8 
11 
100 
60 
11 
2.8 
4.0 
0.4 
0.5 
19 
113 
3.5 
< 0.01 
0.06 
0.06 
45 
132 
0.7 
0.2 
68 
14 
< 0.01 
0.1 
0.5 
0.2 
2.9 
0.07 
1.5 
1.8 
3.5 
0.3 
0.06 
0.3 
0.05 
5.9 
3.3 
< 0.01 
0.05 
IgG, 
Cross-reaction (%) 
2Va 
11 
100 
215 
32 
5.4 
1.0 
0.01 
0.1 
409 
29 
12 
< 0.01 
< 0.01 
0.3 
214 
30 
1.0 
< 0.01 
0.6 
0.4 
< 0.01 
0.07 
< 0.01 
0.2 
0.3 
0.2 
0.8 
0.2 
0.2 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
2.6 
0.09 
< 0.01 
0.8 
IgG, 
4XVIII 
11 
100 
37 
1.7 
1.3 
0.2 
< 0.01 
0.08 
11 
2.2 
0.08 
< 0.01 
< 0.01 
< 0.01 
10 
4.1 
0.08 
0.3 
1.5 
1.8 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
0.3 
< 0.01 
0.1 
0.09 
1.5 
0.07 
< 0.01 
0.01 
< 0.01 
0.2 
0.2 
< 0.01 
0.2 
IgM 
3XIII 
11 
100 
75 
15 
7.8 
11 
0.1 
1.9 
7.2 
545 
2.3 
< 0.01 
< 0.01 
1.5 
230 
210 
1.3 
0.06 
123 
26 
< 0.01 
0.08 
< 0.01 
0.5 
2.2 
< 0.01 
1.1 
1.1 
1.6 
0.07 
< 0.01 
< 0.01 
< 0.01 
6.7 
7.2 
< 0.01 
0.1 
IgG, 
1ab4 
11 
100 
321 
24194 
7.9 
68 
< 0.01 
5.3 
< 0.01 
308 
< 0.01 
< 0.01 
< 0.01 
118 
3214 
222 
< 0.01 
15 
< 0.01 
18 
< 0.01 
79 
40 
727 
323 
108 
153 
4.5 
30 
8.1 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
13 
< 0.01 
0.02 
IgM 
4XVIII 
7 
100 
71 
7.4 
4.9 
0.5 
0.1 
0.2 
75 
9.7 
0.5 
< O.01 
< 0.01 
0.03 
32 
5.3 
0.4 
0.5 
12 
13 
0.01 
0.09 
0.3 
0.1 
0.6 
0.03 
0.1 
0.2 
3.4 
1.8 
0.02 
0.06 
< 0.01 
0.4 
0.7 
< 0.01 
20 
IgM 
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TABLE IB 
Characteristics of monoclonal antibodies raised against progesterone-7a-carboxyethylthioether conjugated 
to bovine thyroid globulin (P-7a-BTG). 
Tracer (P-6/7/1t-HRP) 
Steroid 
progesterone 
11o-hydroxyprogesterone 
11B-hydroxyprogesterone 
16a-hydroxyprogesterone 
17a-hydroxyprogesterone 
20a-hydroxyprogesterone 
20ß-hydroxyprogesterone 
5a-pregnane-3,20-dione 
pregnanedione 
pregnenolone 
17a-hydroxypregnenol one 
5ß-pregnane-3a,206-diol 
pregnanetriol 
11-ketoprogesterone 
5-pregnene-3B,20a-diol 
5S-pregnane-3a,17a,
 0 7 < n „ , ,. „ „, < „ „, 0 5 , 6 „ 6 „ 7 
21-triol-20-one 
1XXI 
6 
100 
55 
0.4 
5.9 
500 
0.3 
1.8 
333 
0.6 
62 
14 
< 0.01 
0.7 
24 
4.0 
2VIII 
6 
100 
< 0.01 
0.9 
0.9 
< 0.01 
0.3 
6.2 
< 0.01 
5.0 
< 0.01 
< 0.01 
< 0.01 
13 
5.5 
22 
Cross-reaction (Ï) 
5X1 
6 
100 
< 0.01 
179 
180 
< 0.01 
11 
65 
1.9 
250 
< 0.01 
< 0.01 
< 0.01 
3.2 
60 
152 
711 
6 
100 
0.5 
71 
57 
4.8 
19 
50 
< 0.01 
400 
< 0.01 
< 0.01 
< 0.01 
37 
400 
267 
7IV 
6 
100 
1.5 
2.8 
64 
12 
392 
27 
17 
4.0 
6.7 
< 0.01 
< 0.01 
< 0.01 
5.7 
9.2 
5XVI 
7 
100 
2.5 
2.2 
42 
13 
382 
17 
32 
2.0 
3.8 
< 0.01 
< 0.01 
< 0.01 
1.3 
8.2 
1XXIV 
7 
100 
1.2 
< 0.01 
46 
13 
64 
5.3 
262 
8.1 
0.1 
< 0.01 
< 0.01 
0.1 
4.6 
11 
8V 
7 
100 
45 
14 
155 
320 
6500 
23 
100 
16 
< 0.01 
< 0.01 
< 0.01 
15 
54 
9.7 
1,4-diene-7o,21-diol-
3,20-dione 
ethiocholanolone 
etiocholan-3,17-dione 
cholesterol 
Cortisol 
cortisone 
corticosterone 
desoxycorticosterone 
aldosterone 
testosterone 
5a-dihydrotestosterone 
5B-dihydrotestosterone 
epitestosterone 
17B-oestradiol 
oestrone 
oestriol 
androsterone 
androstenedione 
androstenone 
Affinity constant (109l/raol) 
0.1 < 0.01 < 0.01 < 0.01 5.4 4.7 4.3 0.2 
Immunoglobulin class 
< 0.01 
0.7 
7.8 
0.2 
0.07 
< 0.01 
2.1 
< 0.01 
7.0 
3.9 
0.4 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
0.1 
< 0.01 
< 0.01 
0.2 
IgG, 
< 0.01 
0.28 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
0.3 
< 0.01 
23 
5.5 
1.5 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
0.5 
l9G2b 
< 0.01 
28 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
1.9 
< 0.01 
44 
0.6 
3.3 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
0.01 
l9G2b 
< 0.01 
18 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
5.1 
1.9 
69 
14 
3.0 
4.0 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
0.01 
igG2b 
< 0.01 
2.7 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
73 
< 0.01 
8.5 
0.8 
0.9 
3.9 
< 0.01 
0.1 
< 0.01 
0.4 
27 
1.1 
0.6 
l9G2b 
0.04 
1.0 
0.08 
0.02 
< 0.01 
0.2 
57 
< 0.01 
10 
0.3 
1.9 
5.7 
< 0.01 
< 0.01 
< 0.01 
0.4 
25 
0.04 
0.6 
l
*b 
< 0.01 
2.6 
0.08 
0.06 
0.09 
0.2 
258 
0.6 
31 
41 
3.2 
13 
< 0.01 
0.08 
< 0.01 
4.0 
104 
1.0 
0.03 
'*2b 
< 0.01 
2.3 
< 0.01 
0.1 
< 0.01 
< 0.01 
3.2 
< 0.01 
5.4 
12.1 
< 0.01 
0.05 
< 0.01 
< 0.01 
< 0.01 
0.5 
1.0 
< 0.01 
0.03 
'<>G2a 
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tracer (P-7-HRP) the affinity for progesterone of antibody 4XVIII increased 
8 10 
from 2 x 10 1/mol to 2 x 10 1/mol. Using P-7-HRP as a tracer, antibody 
4XVIII showed both high affinity and high specificity. For the other anti-
bodies there was no clear cut relationship between specificity and affi-
nity. 
The antibodies produced were mostly of the IgG.. and IgG„, class (Table 
1) . Immunization with P-lla-BSA tended to give rise to IgG.. and IgM mono-
clonal antibodies (for instance antibodies of cell line 4XVIII appeared 
to be of IgM class) and immunization with P-7a-BTG to IeG. and IgG„, anti-
za la 
bodies. Affinity and specificity did not appear to be related to a par-
ticular class of immunoglobulin. 
Sensitivity of the EIA's utilizing the monoclonal antibodies was defined 
TABLE 2 
Sensitivity of anti-progesterone monoclonal antibodies. 
Hybridomas 
Vb7 
Vb8 
2Va 
4XVIII 
3X111 
lab4 
4XVIII 
Hybridomas 
1XXI 
2VIII 
5X1 
711 
7IV 
5XVI 
1XXIV 
8V 
to 
to 
P-lla 
P-7a-
-BSA 
BTG 
Tracer 
(P-6/7/11-HRP) 
11 
11 
11 
11 
11 
11 
7 
6 
6 
6 
6 
6 
7 
7 
7 
HB 
max 
(Pg) 
2,300 
3,000 
300 
1,250 
3,300 
60,000 
18 
2,000 
1,800 
60,000 
120,000 
900 
600 
5,500 
10,000 
Detection limit 
(Pg) 
200 
400 
20 
20 
200 
4,000 
1 
50 
800 
5,000 
10,000 
50 
60 
600 
1,000 
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as 1) the smallest amount of progesterone detectable at the 95% confidence 
limit (detection limit) and 2) the concentration of progesterone causing 
a 50% reduction of maximum binding in the standard curve (hB ), and is 
° max 
shown in Table 2. As expected from affinity constants, sensitivity of the 
antibodies was rather low when P-7-HRP was used as a tracer, except for 
antibody 4XVIII. In contrast to assays with polyclonal antibodies (1,8), 
sensitivity could not be improved by introducing a heterologous (P-6-HRP) 
tracer in the assays with monoclonal antibodies against the 7a-antigen. 
This also contrasts with the improved sensitivity obtained with the anti-
body against the lla-antigen (4XVIII) incubated with P-7-HRP, as compared 
to incubation with P-ll-HRP. Ascites fluid containing antibody 4XVIII had 
the same binding properties as antibodies in the cell culture medium. The 
titer of specific antibody in the ascites fluid was 1:13,500,000, and in 
culture medium 1:12,000. 
Because of the relatively high titer, the high sensitivity, the high 
affinity for progesterone and the relatively low cross-reactivity with 
other steroids, monoclonal antibody of hybridoma cell line 4XVIII was con-
sidered to be useful for standardizing the enzyme immunoassay of milk-pro-
gesterone . 
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Abstract 
Monoclonal antibodies against the H-Y antigen were produced using spleen 
cells from female C57BL/6 mice hyperimmunized with cells from syngeneic 
males. Anti-H-Y-positive clones were detected by enzyme immunoassays. 
Supernatant fluids from Daudi cell cultures and testicular cell prepara-
tions taken from mice, rabbits or calves served as presumptive sources 
of H-Y antigen. In addition, testis supernatant from genetically sterile 
mice was used. Male specificity was ascertained by the fact that the an-
tibodies could be absorbed with spleen cells from male but not from female 
mice. Binding of the antibodies to H-Y antigen on the surface of male and 
female cells, obtained from a number of tissues and species, was confirmed 
by an indirect immunofluorescence assay. Several monoclonal antibodies 
appeared to be positive in all assays tested, suggesting that the molecule 
conferring the H-Y antigenicity lacks species-specificity and appears to 
be identical for soluble and membrane-bound H-Y antigen. 
Introduction 
The H-Y antigen is a minor histocompatibility antigen that is serologi-
cally detectable on the surface of male mammalian cells. It was first re-
cognized in an inbred strain of mice in which the females rejected male, 
but not female, skin grafts (Eichwald and Silmser, 1955). Goldberg et al. 
(1971) later demonstrated that tissue rejection was accompanied by antibody 
formation to the presumptive H-Y antigen. The anti-H-Y antisera could iden-
tify cells from the heterogametic sex in serological systems. Also, murine 
anti-H-Y antisera were shown to cross-react with H-Y on cells from nume-
rous species ranging from fish to man (Wachtel, 1983a). 
There has been some controversy as to whether there are two different 
male-specific antigens, one detected by transplant rejection (the H-Y anti-
gen) and one detected by serological methods (serologically detectable 
male antigen or SDM, Simpson et al., 1982). However, the results of Koo 
and Varano (1981) and Koo et al. (1983) contradicted those of Simpson et 
al. (1982). In addition, Wachtel et al. (1984) reported that the H-Y trans-
plantation and SDM antigens were either identical or highly cross-reactive. 
In this paper, therefore, the term H-Y antigen will be used with the under-
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standing that there is still controversy as to whether SDM and H-Y antigen 
are identical molecules. 
Because of the exclusive presence of H-Y antigen in the mammalian male 
(Wachtel et al., 1975) and its detection early in embryonic development 
(Krco and Goldberg, 1976), it has become possible to predict the phenotypic 
sex of the offspring on the basis of embryonic H-Y antigen expression (for 
reviews, see Booman, 1986; Anderson, 1987). Most experiments designed to 
determine the sex of embryos have been performed with polyclonal antisera 
obtained by hyperimmunizing female mice or rats with syngeneic male spleen 
cells. Although such systems can be accurate (White et al., 1982, 1984), 
the use of polyclonal antisera may give rise to a relatively high degree 
of non-specific background (Piedrahita and Anderson, 1985), probably caused 
by contamination with autoantibodies (Koo et al., 1973). Furthermore, only 
a low percentage of mice have a good antibody response to H-Y antigen and 
their sera are usually low titered and of low affinity. The availability 
of monoclonal anti-H-Y antibodies may resolve some of these difficulties, 
thereby enabling the production of a standardized assay for identification 
of the sex of preimplantation embryos from economically important species. 
We report here the production and characterization of monoclonal antibodies 
against the H-Y antigen which were found to be male-specific on the basis 
of their binding specificity in a variety of tests. 
Materials and Methods 
Production of hybridomas 
Hybridoma cell lines were produced by standard techniques. Female 
C57BL/6 (B6) mice (Harlan Olac) received multiple intraperitoneal injec-
tions of B6 male spleen cells (5 x 10'/dose) over a period of 9 weeks. 
Three to four days before fusion, the animals were boosted intravenously 
with 2.5 x 10' male spleen cells. In total, five fusions between X63-
Ag8.653 myeloma cells and spleen cells from the immunized B6 female mice 
were performed as previously described (Booman et al., 1984). 
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Detection of anti-H-Y antibody production 
Hybridoma supernatants were first screened for the presence of anti-
H-Y antibodies in enzyme immunoassays (EIAs) based on the reaction of se-
creted antibodies and soluble H-Y antigens. Soluble H-Y antigen has been 
detected in a.o. the supernatant fluid of Daudi cell cultures (Nagai et 
al., 1979) and in testicular cell preparations (Müller et al., 1978). We, 
therefore, used testis supernatant (TS) from homogenates of B6 testes pre-
pared according to Wachtel et al. (1980) and Daudi supernatant (DS) from 
Daudi cells cultured according to Nagai et al. (1979). 
Microtiter plate wells were coated with serial dilutions of TS or DS, 
blocked with 2% normal serum from female rabbits and incubated with hybri-
doma supernatants, diluted 1/10 in buffer containing 1% rabbit serum, for 
3 h at room temperature (rT; 21°C). Rabbit anti-mouse Ig antiserum conjuga-
ted to horse-radish peroxidase (RAM-Ig-HRP; Nordic Immunological Laborato-
ries) was then added and the plates were incubated for 2 h in the dark. 
After washing with 0.05% Tween 80, a substrate solution containing tetrame-
thylbenzidine (Fluka) and hydrogen peroxide was introduced. After an incu-
bation period of 45 min the reaction was stopped by adding 4N sulfuric 
acid and the absorbance was measured spectrophotometrically at 450 nm 
(Titertek multiskan). Mouse serum containing polyclonal antibodies against 
the H-Y antigen was used to validate the assays. 
Characterization of anti-H-Y antibodies 
Anti-H-Y antibody-producing clones detecting mouse testicular and Daudi 
H-Y antigens were further tested for their cross-reactivity to soluble 
H-Y antigen from rabbit and calf testes. Preparation of testicular superna-
tants and monoclonal binding assays were performed as described for mouse 
H-Y antigen. 
Additional screening assays were done on TS from genetically sterile 
mice. Two male-sterile karyotypes were used: T(l;13)70H/T(1;13)lWa (De 
Boer et al., 1986) and Is(7;l)40H/+ (Searle et al., 1983). The former type 
was bred by one of us (P. de B.) and identified by peripheral blood culture 
karyotyping and by two sterile matings. The latter was kindly supplied 
by dr. A.G. Searle, Medical Research Council Radiobiology Unit, Chilton, 
Oxon, U.K. 
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Specificity of the EIAs for a male-specific antigen was ascertained 
by serological absorption. Antibody-containing supernatants of positive 
clones were absorbed with spleen cells obtained from male or female B6 
mice and then scored for residual activity in the DS and TS EIAs. For ab-
sorption, aliquots of supernatants (50 ßl) were diluted 1/4 and incubated 
at 4°C for 1 h with 2.5 x 105, 5 x 105, 7.5 x 105 or 1 x 106 splenocytes. 
Subsequently, the cells were discarded and the supernatants diluted to 
1/10, 1/25 and 1/50 for use in the EIAs. As a control, supernatants were 
treated similarly but in the absence of cells. 
In order to evaluate the ability of the anti-H-Y antibodies to bind 
to H-Y antigen present on cell surfaces, supernatants of positive clones 
were tested in indirect immunofluorescence assays on both male and female 
cells. Cell suspensions were prepared from different murine, rat and por-
cine tissues. In the first series of tests, rat and porcine Sertoli cells 
were isolated and cultured according to the procedure of Tung and Fritz 
(1977). After 4-7 days of culture, cells were incubated with diluted super-
natants of anti-H-Y clones for 2 h at rT and washed by centrifugation. 
Subsequently, FITC-conjugated rabbit anti-mouse Ig antiserum (RAM-Ig-FITC; 
Nordic Immunological Laboratories) was added for 1 h at rT in the dark. 
Unbound secondary antibodies were removed by washing and centrifugation 
and the cells were examined under an inverted fluorescence microscope. 
As a negative control, culture supernatant of a rabies-specific monoclonal 
antibody was used. Non-specific binding to female cells was tested on pri-
mary cell cultures of rat ovary cells. 
As suitably matched counterparts, primary cell cultures of male and 
female mouse fibroblasts were compared in reactivity with anti-H-Y anti-
bodies. Male but not female fibroblasts have been found to be positive 
for H-Y antigen (Koo et al., 1981; Müller and Bross, 1979). Fibroblasts 
were isolated and cultured according to procedures described by Koo et 
al. (1981). 
To determine the level of immunoglobulin production and the immunoglo-
bulin (sub)classes of the anti-H-Y antigen clones, microtiter plates were 
coated with RAM-Ig and specific goat anti-mouse (sub)class Ig (Nordic Immu-
nological Laboratories), respectively. The assays were then performed as 
described for the DS and TS EIAs. 
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Results 
Binding of antibodies with Daudi and testis supernatants 
After performing five fusions, we obtained a total of ten hybridoma 
cell lines secreting monoclonal antibodies that reacted with DS in an EIA 
(Table 1). When tested on TS from normal mice, antibodies with low affinity 
for soluble H-Y antigen from Daudi cells were either negative or weakly 
positive, while the high affinity antibodies, as determined by binding 
to DS, reacted strongly with TS (Table 1). No antibodies positive in the 
TS-based EIA and negative in the DS-based EIA were found. 
From Table 1 it can be seen that binding of antibodies to TS from rab-
bits, calves and genetically sterile mice was in the same range as binding 
to DS and TS from normal mice. Although antibodies were raised against 
mouse H-Y antigen, binding of the monoclonal antibodies to rabbit and calf 
TS demonstrates high cross-reactivity with rabbit and bovine H-Y antigen. 
Cross-reactivity with human H-Y antigen can be concluded from binding to 
DS. With one exception, antibodies gave highest binding to TS from Is40H/+ 
sterile mice followed by TS from T70H/TlWa mice and rabbits. 
Protein concentrations of supernatant fluids used for coating varied 
significantly, not only between DS and all TSs, but also between the dif-
ferent TSs (Table 2). Compared with DS, TS is a crude antigen source. The 
amount of TS required for optimal binding of monoclonal antibody 5 XI in 
the EIA (64 or 32 /ig/ml) was large in comparison with the amount of DS 
(10 /ig/ml) . Although the total protein content from rabbit, and particular-
ly from bovine, TS was much higher than from the TS of normal mice, the 
proportion of H-Y antigen to total protein is constant. Evidently, in both 
groups of sterile mice, H-Y antigen represents a larger portion of the 
total protein secreted in the testis than in normal mice. On a total pro-
tein basis two times less TS from sterile than from normal mice was re-
quired for coating. Just as with bovine TS, the high total protein concen-
tration of TS from the T70H/TlWa sterile mice did not influence the rela-
tive amount of H-Y antigen present. 
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TABLE 2 
Protein content of various supernatant fluids and concentration required 
for optimal binding of monoclonal antibody 5 XI to H-Y antigen in these 
fluids. 
Total proteina Protein concentration 
(mg/ml) (/jg/ml) used for coating" 
Supernatant Daudi cells 0.01 10 
Supernatant testis 
Normal mice 7.18 64 
Rabbits 11.99 64 
Calves 35.42 64 
Is40H/+ sterile mice 6.84 32 
T70H/TlWa sterile mice 16.75 32 
aDetermined by standard Coomassie Blue assay for total protein in a sam-
ple with Biorad Protein Assay Kit; after Bradford (1976). 
"Absorbance of 0.9 at 450 nm with 1:10 diluted supernatant of cell line 
5 XI. 
Absorption 
Confirmation of male specificity by absorption revealed that, in gene-
ral, absorption with male spleen cells caused a fall in residual activity 
of the antibodies with both DS and TS. Loss of reactivity after absorption 
with female cells was not more than what could be attributed to non-speci-
fic absorption. Absorption with small numbers of cells caused a slight 
but consistent difference between male-absorbed and female-absorbed anti-
body. A representative test using supernatant from hybridoma cell line 
5 XI is illustrated in Fig. 1. A progressive fall in residual activity 
of the antibodies was observed with increasing numbers of male spleen 
cells. When a large number of cells were used for absorption, however, 
results were not as consistent. 
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Fig. 1. Reaction of monoclonal antibody 5 XI to mouse TS in the EIA after 
absorption with spleen cells from female or male B6 mice. 
Binding of antibodies to cell-surface H-Y antigen 
Characteristic fluorescence patterns of antibodies directed against 
cell-surface antigens were observed in rat and porcine Sertoli cells by 
indirect fluorescence assays. Antibodies 4 VII, 1 III, 5 XI and HY-1, which 
were clearly positive in the EIAs, showed weak lines of fluorescence along 
the cell surface of 15-30% of the cells (Table 1). Some non-specific bind-
ing to ovary cells was observed with all the three monoclonal antibodies 
showing highest anti-H-Y activity in the EIAs (4 VII, 5 XI and HY-1). Non-
specific binding was characterized by homogeneous background fluorescence 
with no obvious cell-surface fluorescence. Antibodies of cell lines 5 X 
and 1 III showed a relatively high background. In experiments on male and 
female mouse fibroblasts, both specific and non-specific patterns of fluor-
escence were similar to those seen on Sertoli and ovary cells, respective-
ly. The intensity of fluorescence, however, was lower in fibroblasts than 
in Sertoli cells. 
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Discussion 
The weak immunogenic character of the H-Y antigen is demonstrated by 
the low number of hybridoma cell lines secreting anti-H-Y antibodies. The 
limited number of clones obtained in five fusion experiments also confirms 
the generally reported poor polyclonal antibody response after hyperimmuni-
zation of female mice with male spleen cells. All but one of the monoclonal 
antibodies are of the IgM class, which is according to expectation, since 
the H-Y antigen is a glycoprotein, the serological determinant most likely 
being a carbohydrate chain with a galactose terminal residue (Shapiro and 
Erickson, 1981). Polysaccharides alone predominantly elicit IgM antibodies 
(see e.g., Kannagi and Hakomori, 1986), with generally low affinity (Klein, 
1982) . In addition, it has been reported that hyperimmunization may also 
cause the forming of IgM antibodies. 
It has been shown previously that monoclonal antibodies against the 
H-Y antigen bind to soluble H-Y antigen in both DS and mouse TS (Brunner 
et al., 1984). For optimal binding, Brunner et al. (1984) coated micro-
titer plates with 5 /Jg/ml DS and 44 jig/ml TS, compared with 10 jig/ml DS 
and 64 /Jg/ml TS in our experiments (Table 2) . The total protein content 
of our TS from normal mice was found to be higher than that reported by 
Brunner et al. (1984) (7.18 vs. 4.40 mg/ml). This could be due to variabi-
lity in the procedure for TS preparation as well as the sexual status of 
the mice. Compared with DS, the H-Y antigen represents only a small portion 
of the total protein secreted in the testis of normal mice. In both lines 
of sterile mice, the proportion of H-Y antigen to total protein appears 
to be higher. Sperm production was absent in both mutants, but activity 
of Sertoli cells was normal. Apparently, the absence of spermatozoa, which 
normally absorb H-Y antigen (Ohno, 1982), increased the relative amount 
of free H-Y antigen. Our data also confirm earlier findings that the 
H-Y antigen is secreted by Sertoli cells (Müller et al., 1978; Zenzes et 
al., 1978) and agree with Brunner et al. (1984) who found that the super-
natant of an established mouse Sertoli cell line contains the H-Y antigen. 
The higher protein content of the T70H/TlWa rete testis fluid compared 
with Is40H/+ and control mice could be due to the fact that cell death 
probably occupies stages in-between mid-pachytene and round plus elongating 
spermatids (De Boer et al., 1986). Thus, before Sertoli cells phagocytose, 
the products of cell degeneration could have added to the high protein 
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concentration in rete testis fluid. Apparently, this is not the case with 
Is40H/+ where cell degeneration uniformly takes place at stage IV of the 
cycle of the seminiferous epithelium (Searle et al., 1983). 
When comparable amounts of protein of TS from rabbits, calves and normal 
mice are coated to microtiter plates, similar rates of binding of the mono-
clonal antibodies are obtained, indicating high cross-reactivity of the 
antibodies with H-Y antigen from different species. These data confirm 
previously reported experiments showing that the H-Y antigen of vertebrates 
and non-vertebrates is either identical or highly cross-reactive (see re-
view by Wachtel, 1983a). 
With regard to the use of bovine TS as the solid phase antigen, it can 
be concluded that the total protein content from bovine TS is higher than 
TS from rabbits and (sterile) mice. However, the proportion of H-Y antigen 
to total protein appears to be constant. As suggested by Bradley et al. 
(1987), bovine TS constitutes an easily obtainable source of large amounts 
of antigenic protein(s) for use in the EIA. 
The similarity in degree of binding to DS/TS, the reduced activity after 
absorption of the monoclonal antibodies with male cells, and the male-spe-
cific fluorescence on intact viable cells demonstrate that the serological-
ly detectable determinants of cell-surface and soluble H-Y antigen are 
either identical or highly cross - reactive. The binding to cell-surface 
H-Y antigen was expected since antibodies were obtained by immunizing fe-
male mice with intact male cells. The slight non-specific binding of 
antibodies from cell lines 4 VII, 5 XI and HY-1 with female cells is remar-
kable because of consistent high anti-H-Y activity in all assays (Table 
1). However, if the monoclonal antibodies are directed to carbohydrate 
moieties, as might be the case according to Shapiro and Erickson (1981), 
slight cross-reactivity with another glycosylated protein present on the 
surface of both female and male cells could be an explanation for our re-
sults. Also, Wachtel (1983b) suggested that H-Y antibodies may be MHC-res-
tricted and may therefore recognize H-Y antigen in association with MHC-
determined antigens, which could result in some non-male-specific binding 
to female cells. Another cause of the non-specific binding might be limited 
expression of H-Y antigen on female cells (Zenzes and Reed, 1984). 
With regard to the choice of type of cells taken for demonstration of 
cell-surface H-Y antigen, Sertoli cells have the advantage that they are 
assumed to have a high level of expression of H-Y antigen. Indeed, with 
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some antibodies (4 VII, 1 III, 5 XI and HY-1), fluorescent lining of the 
cells, a characteristic pattern of cell-surface fluorescence, was observed. 
However, that does not prove male specificity because control female coun-
terparts to Sertoli cells are lacking. Using fibroblasts, a similar but 
weaker fluorescence pattern on male cells was observed, indicating weaker 
expression of the H-Y antigen. 
Finally, the amount of mouse Ig in supernatants of hybridoma cell cul-
tures correlates positively with the results of the DS and TS EIAs, re-
flecting the specificity of the monoclonal antibodies for H-Y antigen. 
For instance, the most promising antibodies (4 VII, 5 XI and HY-1) were 
low titered in the EIA for mouse Ig and less promising antibodies (e.g. 
2 IX, 2 XXIV and 5 X) were high titered, indicating high and low affinity 
for H-Y antigen, respectively. 
In a recent study (Booman et al., 1989) the most promising monoclonal 
antibodies, 4 VII, 5 XI and HY-1, have been evaluated for their efficiency 
in sexing Day 7 bovine preimplantation embryos. 
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Abstract 
Monoclonal antibodies against the H-Y antigen have been used to iden-
tify the sex of preimplantation bovine embryos. In an indirect immunofluo-
rescence assay no clearcut discrimination between positive (male) and nega-
tive (female) fluorescent embryos could be obtained, mainly because of 
non-specific binding of the monoclonal antibodies to the embryonic cells. 
However, after modifying the technique in order to reduce non-specific 
binding, the number of false positives after sexing under these conditions 
was greatly reduced, which suggests that the monoclonal antibodies detect 
a male-specific antigen. Although the H-Y antigen was not detected on about 
half of the male embryos, the experiments indicated that it is possible 
to identify the sex of bovine embryos based on detection of H-Y antigen 
with monoclonal antibodies. 
Introduction 
It is likely that a successful technique for the determination of the 
sex of embryos prior to implantation will be used widely in dairy cattle 
breeding and also will contribute to extension of the use of multiple ovu-
lation and embryo transfer at the commercial level (Booman, 1988). The 
development of several invasive as well as non-invasive techniques for 
sexing bovine embryos has been reported. Invasive techniques include cyto-
logical methods (King, 1984) and chromosome hybridization of Y-chromosome-
specific labeled c-DNA (Leonard et al., 1987). Invasive techniques have 
several disadvantages, such as possible reduced embryo viability owing 
to damage of embryonic cells. Furthermore, embryos cannot be cleaved after 
such treatment. Therefore, non-invasive methods for sexing embryos are 
preferable. Quantification of differences in metabolic activity of X-linked 
enzymes in male and female embryos, based on the assumption that in 
Day 7 bovine embryos X-chromosome inactivation has not yet taken place, 
has been proposed as a non-invasive method (Rieger, 1984). Data from expe-
riments designed to test this hypothesis in the mouse have, however, not 
been encouraging (Williams, 1986). On the other hand, immunological detec-
tion of a male-specific protein, referred to as either the H-Y antigen 
or serologically detectable male antigen, has shown to be a relatively 
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successful non-invasive method of identifying the sex of embryos (for re-
views, see Booman, 1986 and Anderson, 1987). 
As far as we are aware, nearly all experiments to identify the sex of 
embryos based on the detection of the H-Y antigen have been performed with 
polyclonal antibodies generated by hyperimmunizing female mice or rats 
with syngeneic male spleen cells. Monoclonal antibodies, that offer a big 
advantage due to their unlimited availability and their specificity, were 
used in only two studies: White et al. (1983) sexed mouse embryos and 
Wachtel (1984) reported preliminary work on sexing bovine embryos with 
a monoclonal antibody. 
Recently we described the development of monoclonal antibodies to the 
H-Y antigen (Booman et al., 1989). The objective of the present study was 
to determine the discriminating capacity of some of these monoclonal anti-
bodies to sex bovine embryos when used in an indirect immunofluorescence 
assay. Although a discrimination between male and female embryos could 
be made, evaluation of the staining patterns was fairly subjective because 
of non-specific binding of the monoclonal antibodies to the embryonic 
cells. Therefore, a series of experiments with mouse embryos was perform-
ed in order to try to increase the ratio of specific to non-specific bin-
ding. We optimized procedures for washing away unbound antibodies, and 
tried to establish whether IgG-like fragments of the IgM monoclonal an-
tibodies could more easily penetrate the zona pellucida. Varying concentra-
tions of pronase were used to make the zona pellucida more porous. In order 
to increase the fluorescent signal after binding of the anti-H-Y antibody 
to the H-Y antigen, a secondary antibody with a strongly fluorescent label 
was tested. In addition the phenomenon of modulation of the H-Y antigen 
was studied. Based on the results obtained from these experiments a revised 
test was set up. In the present paper the results of sexing bovine embryos 
under "standard" conditions and under "improved" conditions are compared. 
Materials and Methods 
Sexing bovine embryos under standard conditions 
Antibody-producing cells of hybridoma cell line 5 XI (Booman et al., 
1989) were cultured in serum-free medium (HB 102; Hana Media) and super-
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natants concentrated tenfold by Amicon filtration (XM300), aliquoted and 
frozen at -80°C until use. 
Bovine embryos were recovered at slaughter from the uteri of superovu-
lated donor Friesian cows 6-7 days after estrus (Day 0=first day of es-
trus). Non-transferable embryos according to the embryo qualification sys-
tem of Lindner and Wright (1983) were excluded from this experiment. 
Embryos were transferred to a Petri dish containing 1 ml of anti-H-Y 
monoclonal antibody culture supernatant, which had been diluted 1:3 in 
Whitten's medium (WM) pH 7.2 (Whitten and Biggers, 1968) supplemented with 
10% IgG-free heat-inactivated fetal calf serum (FCS) (Gibco), and incubated 
for 90 min. After two 1-min washes followed by a 15-min wash in WM, em-
bryos were incubated for 60 min in the dark in 3 ml goat anti-mouse IgM-
(Fc)-FITC (GAM-FITC) (Nordic Immunological Laboratories) secondary anti-
body diluted 1:200 in WM + FCS. After washing, each embryo was transferred 
to one well of a 24-well plate, containing 2 ml WM + FCS. Fluorescence 
was evaluated by use of an inverted phase contrast microscope (IMT2 Olym-
pus) at 400x magnification. Embryos were classified as either fluorescent 
(H-Y positive) or non-fluorescent (H-Y negative). All procedures were car-
ried out at 22°C. Staining patterns were recorded using a highly sensitive 
SIT video camera (Grundig electronic, SN76). 
Following classification, colchicine (Sigma) at a final concentration 
of 0.5 pg ml was added to each well and after culturing for 3 h at 37°C, 
embryos were karyotyped as described by Dyban (1983). Only 100% readable 
karyograms were taken into account. 
.Reduction of non-specific binding and magnification of positive signal 
Concentrated serum-free supernatant of cell line 5 XI was used for all 
experiments on mouse embryos, with the exception of the fragmentation ex-
periments. For preparation of IgG-like fragments, IgM was isolated from 
ascites fluid of respectively cell lines 5 XI, 4 VII and HY-1 (Booman et 
al., 1989) by subsequent centrifugation, ammonium sulphate precipitation 
and gel filtration on ACA 22 (LKB). Fractions were assessed for the pres-
ence of IgM in an enzyme immunoassay (EIA) detecting mouse Ig (Booman et 
al., 1984). Fragmentation was essentially performed as described by Matthew 
and Reichardt (1982) with minor modifications. 
Mouse embryos were flushed from the oviducts and uteri of mated C57BL/6 
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(Harlan Olac) female mice on the morning of Day 3 (Day 0=day of copulation 
plug). Basically, the incubation with antibody and the recording of fluo-
rescence was as described for the bovine embryos. 
Washing procedure 
Groups of at least 20 mouse embryos were sexed according to the stan-
dard procedures on the understanding that extensive washing steps of res-
pectively two 5-min washes followed by a 10-min wash and two 10-min washes 
followed by a 20-min wash were introduced after incubation with the anti-
H-Y and secondary antibody. Fluorescence patterns were compared with the 
patterns of a group of embryos with the standard washing procedure of two 
1-min washes and a single 15-min wash. 
Accessability of embryonic cells 
Embryos were treated with pronase (Hoechst) in Dulbecco's PBS without 
2+ 2+ Ca /Mg at concentrations of 0.5, 0.25, 0.15, 0.10 and 0.05% during 5 
or 10 min at 37°C in order to find the critical concentration of pronase 
at which the zona was no longer removed. Groups of at least 20 embryos 
were pretreated for various time periods with different concentrations 
below the critical concentration, and then sexed according to the standard 
procedures. Fluorescence patterns of pronase-treated embryos were compared 
with patterns of untreated ones. 
Mouse embryos were sexed with a cocktail of fragmentated 5 XI, 4 VII 
and HY-1 consisting of 0.1 mg ml of each fragment preparation. Except 
for the secondary antibody (rabbit anti-mouse Ig-FITC; Nordic Immunological 
Laboratories) other conditions were identical to the standard procedure. 
Fluorescence patterns were compared with patterns of embryos obtained after 
incubation with a mixture of the purified anti-H-Y antibodies before frag-
mentation at a concentration of 10 pg ml each. 
Modulation of the H-Y antigen 
In order to study whether anti-H-Y monoclonal antibodies induce modu-
lation of the H-Y antigen on the cell surface, groups of at least 20 em-
bryos were sexed either at 4°C both with and without sodium azide (NaN3) 
(0.1%) or at 22°C with NaNß, and fluorescence was evaluated. As a control 
a group of embryos was sexed under standard conditions (22°C without NaNß). 
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Amplification system 
In order to amplify the positive signal resulting from binding of mono-
clonal anti-H-Y antibody to the H-Y antigen, goat anti-mouse IgM(Fc)-R-
phycoerythrin (GAM-RPE) was compared to GAM-FITC on mouse embryos as a 
secondary antibody. RPE produces a signal at least six times stronger than 
FITC (Kroniek and Grossman, 1983). RPE preparations were obtained from 
Biomeda Corp., Foster City, CA., as well as from Southern Biotechnology 
Associates Inc., Birmingham, AL. 
In order to establish the effect of RPE on the viability of mouse em-
bryos, RPE-treated embryos were transferred to the uteri of recipients 
(Balb/c) (Harlan CPB) on Day 2 of pseudopregnancy. Control transfers were 
performed with embryos that were cultured for 2-3 h in VJM + FCS only. 
Sexing bovine embryos under "improved" conditions 
Bovine embryos of 6-7 days old were collected and then sexed with some 
modifications of the standard procedure. A cocktail of purified 5 XI, 4 
VII and HY-1 was used for the first antibody step. Extensive washing proce-
dures of two 10-min and a single 20-min wash were introduced and GAM-RPE 
was the secondary antibody. The whole procedure was performed at 4°C. 
Results 
Evaluation of sexing bovine embryos under standard conditions 
Most bovine embryos flushed at Day 7 were at the early blastocyst stage. 
Three categories of (non-)fluorescent embryos were distinguished: H-Y-posi-
tive embryos, H-Y-negative embryos and an intermediate group of embryos 
(partly assigned as fluorescent or H-Y positive, partly as non-fluorescent 
or H-Y negative). The characteristics of the fluorescence patterns of these 
categories are described in Table 1. 
In lower quality embryos (grades III and IV according to Lindner and 
Wright, 1983) plaques of non-specific fluorescence were often associated 
with dead material or with less viable cells. Fluorescence had to be eva-
luated on the basis of the viable part of the cell mass. Lower quality 
embryos led to a more subjective evaluation and required more experien-
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ce. The numbers of embryos with a fully readable karyogram in the different 
quality classes were too small, however, to calculate a correlation between 
misclassification and quality of the embryos. 
A total of 112 bovine embryos were evaluated for expression of H-Y anti-
gen; of these, 63 (56%) were classified fluorescent and 49 (44%) non-fluo-
rescent. From 30 embryos a readable karyogram was obtained. Twenty-three 
embryos (77%) were assigned correctly: 10 out of 16 (63%) as H-Y-positive 
classified embryos and 13 out of 14 (93%) as H-Y-negative classified em-
bryos. Detailed results are given in Table 2, from which it can be con-
cluded that all misclassifications are in the relatively large intermediate 
group of embryos. The larger number of fluorescent as compared to non-fluo-
rescent embryos seems to be a consequence of the false H-Y positives in 
this intermediate group of embryos. 
Seduction of non-specific binding and magnification of positive signal 
Sexing mouse embryos under standard conditions 
Flushing of uteri of mice at Day 3 resulted mostly in embryos at the 
morula to early blastocyst stage. Sexing under standard conditions did 
not give a clearcut discrimination between H-Y-positive and H-Y-negative 
embryos. Staining ranged from highly fluorescent to non-fluorescent. Depen-
ding on the intensity of staining, embryos showing intermediate fluores-
cence were more or less subjectively assigned to the group of H-Y-positive 
embryos or to the group of H-Y-negative embryos. In Table 3 characteristic 
patterns of fluorescence are described for H-Y-positive and H-Y-negative 
mouse embryos when sexed under standard conditions. 
Washing procedure 
More extensive washing procedures resulted in a better discrimination 
between H-Y-positive and H-Y-negative embryos. In Table 4 changes in fluo-
rescence characteristics for both positive and negative embryos are descri-
bed after washing for 10, 10 and 20 min compared with characteristics after 
washing for 1, 1 and 15 min (standard procedure). 
Accessibility of embryonic cells 
Pretreatment of mouse embryos with 0.15% pronase for 5 min appeared 
to be the critical point for removal of the zona pellucida. Pretreatment 
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with 0.10 and 0.05% pronase for 5 and 10 min at 37°C and subsequent sex-
ing resulted in more and more intensive staining compared with staining 
of control embryos without pronase treatment. The zona pellucida was highly 
fluorescent under these conditions. There were no non-fluorescent embryos. 
Although after pretreatment with 0.01% and even lower percentages of pro-
nase fluorescence patterns resembled those on control embryos, intensive 
staining of the zona remained a major problem. As a consequence no discri-
mination could be made between H-Y-positive and H-Y-negative embryos after 
pronase treatment. 
After fragmentation of the IgM monoclonal antibodies, fragments exhi-
bited a reduced capacity to bind to H-Y antigen in a testis supernatant 
EIA (Booman et al., 1989) as compared with the intact antibodies. Not sur-
prisingly, the mouse embryos sexed with a cocktail of fragmentated 5 XI, 
4 VII and HY-1 showed only a very diffuse background fluorescence, caused 
by the secondary antibody. Results with a cocktail of the purified anti-
H-Y monoclonal antibodies before fragmentation were about the same as with 
unpurified supernatant of antibody 5 XI alone. With the cocktail no impro-
vement of positive signal was observed. 
Modulation of the H-Y antigen 
Performance of the indirect assay at 4°C resulted in many fluorescent 
spots in between the embryonic cells and the zona pellucida. By introdu-
cing prolonged washing steps this phenomenon could be prevented. The combi-
nation 4°C/longer washing steps led to a magnified positive fluorescence 
signal and a more clearcut discrimination between H-Y-positive and H-Y-
\ 
negative embryos (Table 5). Addition of 0.1% NaN3 to all media either in 
combination with 4°C or with 22°C gave about the same staining patterns 
as when performed at 4°C alone. 
Amplification system 
Staining with GAM-RPE as a secondary antibody was somewhat brighter 
than with GAM-FITC, and resulted in a more clearcut discrimination between 
positive and negative embryos. Fluorescence patterns were about the same 
as with GAM-FITC. Fluorescence of GAM-RPE, however, tended to bleach rather 
rapidly and both RPE preparations used bound somewhat non-specifically 
to the zona pellucida. 
Pregnancy rate for both GAM-RPE treated embryos and control embryos 
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was about 20% (142 and 105 embryos were implanted, respectively) from which 
it can be concluded that RPE does not affect viability of embryos. 
Evaluation of sexing bovine embryos under "improved" conditions 
Most bovine embryos flushed at Day 6-7 were morulas and early blasto-
cysts. The indirect fluorescence assay with improved conditions resulted 
in a somewhat less subjective assignment of sex because of a more marked 
difference between positive- and negative-staining embryos. However, as 
in mouse embryos, GAM-RPE bound non-specifically to the zona pellucida. 
This non-specific fluorescence might overshadow specific fluorescence of 
low intensity on the embryonic cells. As with sexing under standard condi-
tions three categories of (non-)fluorescent embryos were distinguishable 
(Table 6). 
A total of 96 bovine embryos were evaluated for expression of H-Y anti-
gen; of these, 40 (42%) were classified fluorescent, 53 (55%) non-fluo-
rescent and 3 (3%) non-sexable because of fluorescence of the zona. From 
22 embryos a readable karyogram was obtained. Sixteen embryos (73%) were 
assigned correctly: 6 out of 6 (100%) as H-Y-positive classified embryos 
and 10 out of 16 (63%) as H-Y-negative classified embryos. Detailed re-
sults are given in Table 7, from which it can be concluded that nearly 
all misclassifications are in the category of H-Y-negative embryos. The 
larger number of non-fluorescent as compared to fluorescent embryos seems 
to be a consequence of the false H-Y negatives in that category. All fluo-
rescent embryos were males. The intermediate group of embryos was relative-
ly small compared with sexing under standard conditions. 
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Discussion 
Although bovine embryos could be sexed under standard conditions with 
an accuracy of 77%, evaluation of the staining patterns was fairly sub-
jective. Sexing resulted in more false positives than false negatives. 
This is probably caused by non-specific binding of the monoclonal anti-
bodies to the embryonic cells, which overshadows low intensity specific 
fluorescence. White et al. (1983) using monoclonal antibodies and 
Piedrahita and Anderson (1985) using polyclonal antibodies reported like-
wise that in murine embryos the proportion of embryos classified as 
H-Y positive tended to be larger than the proportion of embryos classi-
fied as H-Y negative. In addition, data reported by White et al. (1984) 
indicated a similar although non-significant trend with bovine embryos. 
If the monoclonal antibodies or most of the immunoglobulins in a polyclo-
nal antiserum are directed to carbohydrate moieties, as might be the case 
according to Shapiro and Erickson (1981), slight cross-reactivity with 
another glycosylated protein present on the surface of both female and 
male cells could be an explanation for finding more fluorescent than non-
fluorescent embryos. Also, Wachtel (1983) suggested that humoral H-Y anti-
bodies may be major histocompatibility complex (MHC)-restricted and H-Y 
antibodies may therefore recognize H-Y antigen in association with MHC-
determined antigens, which could result in some non-male-specific binding 
to female cells. Another cause of the false positives might be limited 
expression of H-Y antigen on female cells (Zenzes and Reed, 1984). 
A more trivial cause for non-specific binding might be that the zona 
pellucida presents not only a barrier for the intrusion of anti-H-Y anti-
bodies, but also for the diffusion of the unbound antibodies. The large 
molecular size of the IgM antibody might hamper its penetration through 
the zona, although Sellens and Jenkinson (1975) have reported that not 
only IgG, but also IgM molecules can penetrate the zona pellucida of mouse 
embryos. The rate of passage, however, may be critical. Prolonged washing 
steps indeed diminished non-specific binding. Acceleration of the diffusion 
process by making the zona more porous, however, did not succeed. Pronase 
has been reported to be effective in lysing zonae of mouse blastocysts 
(Bowman and McLaren, 1970). Although in our experiments mouse embryos were 
pretreated with much lower pronase concentrations than normally used for 
zona removal (0.5%), at all concentrations non-specific binding increased, 
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probably due to damage of the embryonic cells and the zona itself. Because 
a cocktail of fragments of monoclonal antibodies did not result in any 
specific fluorescence, it could not be clarified whether IgG-like fragments 
can more easily penetrate the zona than the intact IgM molecules. It may 
be that fragmentation resulted in damage of the antigen binding site and 
subsequent loss of binding capacity of the antibodies. Another possibility 
may be that modifications occur in that part of the Ig molecule that binds 
with secondary antibody. 
With regard to the magnitude of the specific signal, modulation of the 
H-Y antigen seems to be partly responsible for the weak fluorescence when 
sexed under standard conditions. The phenomenon of antigenic modulation 
has been first described by Boyse et al. (1967). Modulation is the result 
of internalization of the antigen and the bound antibody. This is typically 
preceded by capping of the antibody-antigen complex, a process during which 
the complex appears to localize to one region of the cell surface. Capping 
is an active, temperature- and metabolically dependent process (Taylor 
et al., 1971). With mouse lymphocyte-surface immunoglobulin molecules cap-
ping was inhibited both at 0°C and at 20°C with NaN3 or dinitrophenol. 
Modulation has also been described for H-2 antigens on the embryonic cell 
surface (Geib et al., 1976). Our results confirm those findings for the 
H-Y antigen. Because NaN3 might harm viability of the embryos, working 
at 4°C will be preferable to inhibit the process of modulation. The low 
temperature might also prevent possible shedding of the H-Y antigen (Black, 
1980). In spite of some disadvantages, as we have seen in our experiments, 
the use of other fluorescence markers like phycoerythrins can also contri-
bute to magnification of the positive signal. 
When applying results obtained with mouse embryos to bovine embryos, 
we have to keep in mind that in case of sexing under standard conditions, 
fluorescence patterns in mouse embryos differed from those in bovine em-
bryos . The murine monoclonal antibodies might bind to the mouse embryos 
in a more non-specific manner because of cross-reactivity with related 
antigens or binding to possible Fc-receptors on the surface of embryonic 
murine cells. Furthermore, the under standard conditions regularly occur-
ring spots of fluorescence within the perivitelline space of mouse embryos 
indicate a difference in permeability of the zonae pellucidae. 
Nevertheless, sexing bovine embryos under improved conditions resulted 
in greatly reduced non-specific binding, a more clearcut discrimination 
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between H-Y-positive and H-Y-negative embryos, as well as in a smaller 
intermediate group of embryos. In addition, there was a shift from too 
many positives to only false negatives. This indicates that there is no 
expression of the H-Y antigen by female embryos, as Zenzes and Reed (1984) 
suggest, or at most at a very low level, and that no or very little cross -
reactivity with MHC-determined antigens occurs, as has been suggested by 
Wachtel (1983). No false positives also means that the assay is male speci-
fic. Although the monoclonal antibody used in this experiment showed a 
very slight cross-reactivity with primary cultures of female fibroblasts 
and ovary cells (Booman et al., 1989), this appeared not to interfere with 
the fluorescence staining of embryos. The occurrence of false-negative 
embryos might be caused by a weak expression of the H-Y antigen and/or 
a low affinity of the monoclonal antibody for bovine H-Y antigen combined 
with a not fully amplified signal in the assay. In addition, the non-speci-
fic binding of the fluorescence marker to the zona might overshadow low 
intensity fluorescence on the embryonic cells. 
With regard to the low affinity to the H-Y antigen, it has been pro-
posed that the serological determinant of H-Y antigen consists of a car-
bohydrate chain with a galactose terminal residue (Shapiro and Erickson, 
1981). Polysaccharides alone predominantly elicit IgM antibodies (see, 
e.g. Kannagi and Hakomori, 1986) with generally low affinity (Klein, 1982). 
It has also been observed that during the early development of the mouse, 
changes in cell-surface carbohydrates occur so that sialic acid masks mole-
cules on the surface of trophoblasts at the time of implantation (Martico-
rena et al., 1983). Because of the likelihood of carbohydrate side chain 
modifications or variable biosynthetic reactions occurring during early 
cell-surface antigen expression in developing embryos, antibodies recog-
nizing amino acid structural epitopes of H-Y antigen might be more appro-
priate as reagents for an immunological sexing test. Although the anti-
bodies used in our experiments were selected on basis of their binding 
to both soluble and cell-surface H-Y antigen originating from different 
sources (Booman et al., 1989), for a highly discriminating sensitive assay 
selection on high affinity antibodies for protein structural determinants 
on bovine cell-surface H-Y antigen needs more attention. 
In the study of White et al. (1983), in which they also used monoclonal 
antibodies against the H-Y antigen in a comparable indirect fluorescence 
assay, the overall accuracy in identifying the sex of mouse embryos was 
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81%. In mouse experiments at our laboratory a percentage of 72% was obtain-
ed (data not shown). Based on validated polyclonal antibodies the sex of 
bovine embryos was identified with an overall accuracy of 84% (White et 
al., 1984, 1987), compared with 77 and 73% obtained in our experiments 
using monoclonal antibodies. Apart from the limited availability of the 
polyclonal antiserum, the latter shows that polyclonal antibodies may prove 
useful. The better results obtained by White et al. might be a consequence 
of selection on quality of the embryos. In our experiments no selection 
on quality was made and quality is an important factor for interpreting 
results of the test. Selection on good quality embryos may also account 
for the high percentage of readable karyograms White et al. obtained (46-
58% vs. 33-59% in the literature; see King, 1984). Since in embryo transfer 
programs a considerable part of the embryo population is of lower quality, 
an assay for sexing embryos has to include all these embryos. It remains 
to be seen whether the accuracy of the assay can be improved by preparation 
of high affinity monoclonal antibodies and by amplification of the posi-
tive fluorescence signal. 
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Abstract 
The effect of murine anti-progesterone monoclonal antibodies on plasma 
progesterone levels was studied in cyclic pigs. Intravenous injection of 
increasing amounts of anti-progesterone antibodies resulted in a concomi-
tant rise in levels of antibody-bound progesterone. At the same time a 
significant rise in plasma concentrations of total progesterone was ob-
served immediately after administration of higher doses of antibodies. 
The net effect of progesterone binding by the monoclonal antibody was sig-
nificant for the group of animals injected with at least 50 mg of anti-
body. The effect, however, was relatively small and more or less indepen-
dent of the quantities of antibody administered. Plasma levels of circu-
lating antibody capable of binding progesterone were still detectable at 
the end of the experimental period. On the other hand it appeared that 
in all animals, except the one injected with the largest quantity (500 
mg) of antibody, the concentration of antibody-bound progesterone started 
to decrease as early as the first day after injection and was below de-
tectable levels within one or two days. Mechanisms that may control the 
initial increase in progesterone levels and enable the animals to main-
tain adequate levels of free progesterone in circulation are discussed. 
Administration of a minimum dose of 32 mg antibody resulted in an anti-
mouse immune response after the first injection, and subsequently in a 
neutralization of the anti-progesterone monoclonal antibodies immediately 
after the second injection. When smaller quantities of antibody (< 20 mg) 
were used, anti-mouse antibodies were detected only after the second or 
third injection. 
Introduction 
The neutralization of hormones by specific antibodies has been exten-
sively used to study endocrine systems in vivo. Active immunization against 
steroid hormones, for instance, may either enhance or limit fertility, 
particularly in females (Webb et al., 1984). Immunoneutralization by active 
immunization, however, is not always reproducible. Within species, and 
even within breeds, marked variations in the magnitude and speed of anti-
body response may occur. These variations may be circumvented by passive 
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immunization with monoclonal antibodies which, by definition, have identi-
cal characteristics. 
Several passive immunization experiments with murine anti-progesterone 
monoclonal antibodies have been performed in mice and ferrets to study 
the ways by which progesterone acts on the female reproductive tract during 
the earliest stages of gestation (Wright et al., 1982; Wang et al., 1984; 
Rider et al., 1985; Rider and Heap, 1986). In mice and ferrets anti-proges-
terone antibodies can block implantation (Wright et al., 1982; Wang et 
al., 1984; Rider and Heap, 1986). The mechanism behind this phenomenon 
is still unclear. In general, it is believed that immunization results 
in a reduction of the amount of progesterone freely available in circula-
tion to interact with target cell receptors. The reduction in fertility 
caused by the anti-progesterone antibodies can be reversed by administra-
tion of an equivalent amount of free hormone (Rider et al., 1985). However, 
in all experiments the concentration of total progesterone in plasma was 
manifold higher in the experimental than in the control group of animals. 
Although a reduction in free/total progesterone ratio was observed after 
administration of anti-progesterone antibodies, the absolute amount of 
free progesterone (i.e., not bound to binding proteins or antibody) in-
creased at the same time (Cheesman and Chatterton, 1982; Nowak et al., 
1986) . A mechanism might be proposed by which transient decreases in levels 
of free progesterone, of which normally 95% is bound to proteins like al-
bumin and glucocorticoid binding globulin (CBG) (Hoffmann et al., 1969), 
are compensated by a rapid dissociation of free progesterone from the CBG-
progesterone pool. 
In order to further elucidate the mechanism by which steroid levels 
are regulated, we studied the effect of murine anti-progesterone monoclonal 
antibodies on plasma levels of total and non-antibody-bound progesterone 
in cyclic pigs. Since murine monoclonal antibodies, when used in the pig, 
may elicit an anti-mouse immune response which might block their capacity 
to neutralize progesterone, we also investigated whether an anti-mouse 
immune response occurs after repeated administration. Part of this study 
has been published previously in abstract-form (Booman et al., 1984b). 
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Materials and Methods 
Animals 
Thirteen nulliparous female pigs (Dutch Landrace x Great Yorkshire), 
7-9 months old and weighing + 100 kg, were housed individually and fed 
according to their requirements. Occurrence of oestrus was checked twice 
daily by observation of vulval swelling and by exerting pressure on the 
back of the gilts. The first day of standing heat was defined as Day 0 
of the oestrous cycle. After two regular cycles and at least 10 days before 
the experiment started, the animals were chronically cannulated as des-
cribed by Van de Wiel and Eikelenboom (1977). 
Monoclonal antibody 
Monoclonal antibodies (MCAs) against progesterone were produced as des-
cribed by Booman et al. (1984a). The immunogens used were progesterone-lla-
hydroxy-hemisuccinate conjugated to bovine serum albumin (P-lla-BSA) and 
progesterone-7oj-carboxyethylthioether conjugated to bovine thyroid globulin 
(P-7a-BTG). For our experiments antibody 4 XVIII, raised against P-lla-
BSA was selected. This antibody showed low cross-reactivity with a large 
series of related steroids. In a double antibody heterologous solid phase 
enzyme immunoassay (EIA) the association constant (K^) of the MCA for pro-
gesterone was 2 x 10 1/mol (Booman et al., 1984a); it should be noted, 
however, that this K^ may be dependent on the type of assay (Van Weemen, 
1974). Ascites fluid of cell line 4 XVIII was pooled and its titer (defined 
as the working dilution when tracer binds 50% of maximum binding in the 
EIA-system) determined at 1:13,500,000. Serum-free cell culture supernatant 
(HB 102; HANA Media) was produced and tenfold concentrated on an XM-50 
Dlaflo membrane (Amicon Corp.). The titer of the concentrated serum-free 
supernatant was 1:120,000. 
The immunoglobulin M (IgM) concentration of both antibody preparations 
was determined by EIA. Briefly, microtiter plates were coated with rabbit 
anti-mouse Ig antiserum (RAM-Ig; Nordic Immunological Laboratories). Four-
fold serial dilutions of purified mouse myeloma IgM (Sigma Chemicals) from 
25 /ig to 1.5 ng per 100 ^ 1 and of both antibody preparations were added 
and bound IgM was quantified by subsequent incubation with RAM-Ig conjuga-
77 
ted to horse-radish peroxidase (HRP) (Nordic Immunological Laboratories). 
Detailed procedures for the EIA were similar to those described earlier 
(Booman et al., 1984a). Concentrations of IgM in ascites and serum-free 
supernatant were 100 and 2 mg/ml, respectively. Although the ascites fluid 
was produced in male mice, it appeared that clarified ascites contained 
about 3.7 /ig progesterone per ml as determined by radio immunoassay (Van 
de Wiel et al., 1981); this progesterone is probably produced by the andre-
nal gland. In the concentrated serum-free supernatant no progesterone could 
be detected (< 0.1 ng/ml). 
Experimental design and blood sampling 
Three different experiments were performed. In the first one, 6 gilts 
were injected intravenously on Day 12 + 1 of the oestrous cycle with 10 
ml aliquots of ascites fluid diluted with 0.9% NaCl, containing 50, 100, 
200, 300, 400 and 500 mg IgM, respectively. Blood samples were collected 
once a day during the whole cycle and frequently on the day of MCA-admini-
stration according to the following scheme: at 155, 95, 65, 35 and 5 min 
before and at 2, 4, 6, 8, 10, 15, 20, 25, 35, 45, 55, 85, 115, 145, 175 
and 205 min after administration and further on every hour for the next 
four hours. In the second experiment, 2 gilts were injected intravenously 
three times with 10 ml of concentrated serum-free supernatant containing 
20 mg IgM with intervals of 14 days and starting on an arbitrary day of 
the cycle. Blood samples were taken once a day starting from at least 14 
days before the first injection until 14 days after the last injection. 
The third experiment was similar to the first one, except that 4 gilts 
were injected with 10 ml aliquots of concentrated serum-free supernatant 
diluted with 0.9% NaCl, containing 2,4, 8 and 16 mg IgM, respectively, 
and 1 gilt was injected with 16 ml of supernatant containing 32 mg IgM. 
In this experiment the injections of IgM were repeated during the next 
oestrous cycle, using the same IgM concentrations. 
Blood samples were collected in heparinlzed tubes on ice and the plas-
ma, separated by centrifugation at 1600g for 10 min at 4°C, was stored 
at -20°C. 
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Enzyme immunoassays 
Total progesterone 
After extraction of progesterone from plasma, total progesterone (P) 
was determined by EIA as described by Van de Wiel and Koops (1986). Plas-
ma samples were diluted 1:10 with assay buffer and 20 /il of diluted sam-
ple was extracted with 1.75 ml of diethylether. The contents of each tube 
was mixed on a Vortex mixer and allowed to stand for at least 15 min at 
-30°C. The ether fraction was decanted into a clean tube and evaporated 
under a N2-stream in a waterbath (40°C) , after which 500 fil of assay buf-
fer was added to each tube. The tubes were shaken gently (Vortex) and incu-
bated for at least 30 min. Next, 100 pi aliquots of the extracts were incu-
bated in duplicate in microtiter plate wells (Costar) coated with rabbit 
anti-P-7a-BSA antiserum. Standard amounts of progesterone (0-200 pg/ml, 
100 jjl/well) were incubated in quadruplicate. HRP conjugated to progeste-
rone-6j8-hydroxy-hemisuccinate (P-HRP) was used as a tracer. 
Non-MCA-bound progesterone 
In order to determine the plasma levels of non-MCA-bound progesterone, 
samples were precleared of monoclonal antibodies using ammonium sulphate 
precipitation (experiment 1) or absorption with donkey anti-mouse Ig 
coupled to cellulose (SacCel; Wellcome Research Laboratories) (experiments 
2 and 3). The levels of progesterone were measured as described above. 
Because of the limited binding capacity of SacCel, plasma samples were 
diluted before absorption. Appropriate dilutions were determined beforehand 
by screening serial dilutions of plasma samples from every animal in an 
EIA for residual mouse IgM after SacCel absorption. 
In order to correct for the dilution and a-specific loss of progesterone 
during the absorption procedures, the levels of non-MCA-bound P for each 
animal were corrected in such a way, that the mean levels of total P and 
non-MCA-bound P before the first injection were equal. 
à 
Circulating MCA capable of binding progesterone 
Plasma levels of circulating MCA still capable of binding progesterone 
(MCA - (P-MCA)) were determined in the EIA as described by Booman et al. 
(1984a). Briefly, microtiter plates were coated with RAM-Ig. After incu-
bation with the plasma samples, bound MCA capable of binding progesterone 
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was detected by incubation with P-HRP. 
Anti-mouse MCA response 
Microtiter plates were coated with anti-progesterone monoclonal anti-
body 4 XVIII (1.8 /ig IgM/ml, 100 /jg/well) . Plasma samples were added and 
the assay developed with rabbit anti-swine Ig conjugated to HRP (Nordic 
Immunological Laboratories). Detailed assay procedures for the EIA were 
similar to those described earlier (Booman et al., 1984a). 
Statistical analysis 
Means and corresponding standard deviations were calculated. Levels 
of total progesterone and non-MCA-bound progesterone before and at dif-
ferent time periods after injection were compared with the sign-test. Un-
less stated otherwise, a two-sided test with a level of significance of 
0.05 was used. 
Results 
Plasma levels (means + s.d.) of total progesterone, non-MCA-bound pro-
gesterone and MCA-bound progesterone (P~MCA) from the gilts in the first 
experiment immediately before and at different time periods after injection 
of various quantities of IgM from ascites fluid are listed in Table 1. 
P~MCA was calculated as the difference between total P and non-MCA-bound 
P. The results indicate that anti-progesterone MCAs do bind to progesterone 
in vivo. In general, increasing quantities of IgM administered correlate 
with increasing amounts of progesterone bound to MCA. Plasma levels of 
total P and non-MCA-bound P could again be superimposed after a period 
of 24 h, with exception of the gilt injected with the largest quantity 
of IgM (500 mg) in which non-MCA-bound P levels equaled those of total 
P after about 7 days (Fig. 2). 
Immediately after injection of the MCAs there is a significant rise 
(p < 0.05) in plasma levels of total P, with a higher rise if more anti-
body is injected. P~MCA, calculated as the difference between total P and 
non-MCA-bound P, gives a good estimate of the actual amount of progesterone 
bound by MCA. However, in order to determine the net effect of progesterone 
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binding by MCA, the difference between non-MCA-bound P immediately before 
and at different periods after injection was calculated. The levels of 
non-MCA-bound P at all time periods after injection are significantly re-
duced (p < 0.05) compared to values obtained before injection, with excep-
tion of the 3-8 h period. The results presented in Table 1 suggest that 
this reduction, or the net effect of progesterone binding by MCA, is more 
or less independent of the quantities of IgM injected. 
A rise in plasma levels of circulating MCA capable of binding proges-
terone was observed immediately after injection. The MCAs were still de-
tectable by EIA at the end of the experimental period. As typical exam-
ples of this experiment, progesterone and MCA levels of two gilts are shown 
in Figs. 1 and 2. 
In the second experiment the first blood sample was taken 24 hours after 
injection, when according to the results of experiment 1 the transient 
increase in total P as well as the difference between total P and non-MCA-
bound P had subsided. Both gilts generated an anti-mouse immune response 
after injection with the MCAs. In gilt Ac 1 a rapid increase in the amount 
of antibodies against the mouse MCA can be detected after the second in-
jection. This increase continues after the third injection (Fig. 3). In 
the other gilt anti-mouse levels do not rise until 2 days after the third 
injection (= 16 days after the second injection). In Fig. 3 plasma levels 
of total P, non-MCA-bound P, circulating MCA capable of binding P and the 
anti-mouse immune response are shown for one of the two gilts (Ac 1) in 
this experiment. 
Data from the third experiment are listed in Table 2. In the gilts in-
jected with concentrated serum-free supernatant no significant increase 
in levels of total P occurs immediately after injection (p = 0.054, one-
sided). As in experiment 1, the net effect of progesterone binding by MCA 
is calculated as the difference between levels of non-MCA-bound P before 
and after injection. No significant (p < 0.05) difference could be found 
in this respect. 
Results of experiments 1 and 3 have been combined in Table 3, showing 
the amounts of progesterone that theoretically can be bound by the anti-
bodies as compared to the amounts of actually bound progesterone (P~MCA) 
in the period 0-0.5 h after injection. 
In the third experiment a minimum injected dose of 8 mg IgM results 
in a detectable rise in MCA capable of binding progesterone. As early as 
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the first day after administration 'unbound' MCA levels begin to decline, 
reaching preinjection levels after two days. In the animal injected with 
32 mg of IgM no rise in unbound MCA can be observed after the second in-
jection (Fig. 4). In this gilt anti-mouse antibodies can be detected in 
plasma 10 days after the first injection. After the second injection the 
anti-MCA response becomes very pronounced. A very slight anti-mouse res-
ponse is seen after the first injection in the gilt that was treated with 
8 mg IgM, which response becomes more evident after the second injection. 
No clear responses of anti-mouse Ig after either injection could be ob-
served in the gilts injected with 2, 4 or 16 mg of IgM. 
Discussion 
Immunization with anti-steroid MCAs may modulate the reproductive func-
tion in domestic animals. To further elucidate the mechanism by which ste-
roid levels are regulated, in the present study the efficacy of anti-pro-
gesterone monoclonal antibodies on the possible reduction of plasma proges-
terone levels in cyclic pigs was examined. Results from the first expe-
riment, in which large amounts of IgM monoclonal antibodies directed 
against progesterone were administered, indicate that the antibodies do 
bind to progesterone in vivo. Administration of increasing amounts of anti-
body resulted in dose-correlated rises in amounts of progesterone actually 
bound by the antibody. However, although theoretically enough antibodies 
had been administered to bind most or all progesterone in circulation (88 
to 1238%, Table 3), non-MCA-bound P was not reduced to basal levels. 
In all animals, except the one injected with 500 mg IgM, the concen-
tration of antibody-bound progesterone started to decrease on the first 
day of injection. No antibody-bound progesterone, calculated as the dif-
ference between total and non-MCA-bound P, could still be observed with-
in one or two days after administration. The antibody-bound progesterone 
immune complexes, together with antibodies still capable of binding pro-
gesterone, were relatively rapidly cleared from the circulation. In ad-
dition, an equilibrium was established between the free steroid, steroid 
bound to antibody, and steroid bound to binding proteins. The discrepancy 
between the presence of circulating anti-progesterone antibodies and the 
absence of antibody-bound progesterone suggests that a substantial number 
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reet resorption of progesterone from body tissues with a subsequent in-
crease in total progesterone levels in the circulation. Such a release 
of progesterone from body tissues would be an acceptable explanation for 
the observed increase in progesterone levels that parallels the increasing 
quantities of administered antibodies in our experiments, especially since 
it is known that in the pig about 200 times more progesterone is stored 
in the adipose tissue than the amount present in total blood, corresponding 
to the daily production of the corpora lutea of a sow on Day 11 of the 
cycle (Hillbrand and Elsaesser, 1983). 
Nowak et al. (1986) and Cheesman and Chatterton (1982) found that anti-
body administration decreases the percentage, but increases or maintains 
the absolute amount of free progesterone present in circulation (i.e. not 
bound to binding proteins or antibody). These data seem to point to a me-
chanism which enables the animal to maintain adequate levels of free pro-
gesterone in circulation. The rapid decline in levels of antibody-bound 
progesterone observed in our present experiments supports the concept of 
such a mechanism. 
On the other hand, this suggested mechanism of the animal to maintain 
its progesterone levels seems to contradict the observations of a.o. Wang 
et al. (1984), Rider and Heap (1986) and Phillips et al. (1988) that anti-
progesterone monoclonal antibodies can block pregnancy in mice, ferrets 
and rats. Recent studies (Wang et al., 1988), however, have revealed that 
only at a critical stage in early development the administration of large 
amounts of anti-progesterone antibody may locally inhibit the uterine up-
take of progesterone, which in turn prevents implantation in mice. 
The second and third experiment show that repeated administration of 
relatively small amounts of monoclonal antibodies may elicit an anti-mouse 
response in the pig. In the gilt injected with 32 mg of MCA, a clear anti-
mouse response was already observed after the first injection. The anti-
MCA antibodies may be an explanation for the observation that no MCA capa-
ble of binding progesterone was detectable after the second injection with 
32 mg of antibody. Phillips et al. (1988) did not observe a decreased ef-
ficacy of anti-progesterone monoclonal antibodies after repeated admini-
stration in rats, although much more antibody had been injected (on a dose 
per kg body weight basis) than in our experiments. This discrepancy may 
be due to the greater homology between immunoglobulins of mouse and rat 
than of mouse and pig, resulting in a more pronounced anti-mouse Ig res-
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of IgM binding sites remains unoccupied, as was previously observed by 
Ellis et al. (1988). They found that only 1-4% of the IgM sites is occupied 
by progesterone. 
Administration of anti-progesterone monoclonal antibodies resulted in 
a significant rise in plasma concentrations of total P. Progesterone from 
the ascites fluid itself may have contributed to the increase in total 
P concentration after injection for only a small part. Based on 3.7 /ig 
P/ml ascites fluid and on a total plasma volume of 5 liters, 1 ml ascites 
may maximally account for a rise in total P of 0.7 ng/ml plasma. Although 
the net effect of binding progesterone by antibody was significant, the 
effect was relatively small (0.1 - 10.9 ng/ml) and, within the range of 
50-500 mg IgM, more or less independent of the quantities of IgM injected. 
In the third experiment no significant rise in levels of total P nor 
a clear reduction of non-MCA-bound P could be observed. Theoretically, 
110.5% of progesterone present in circulation can maximally be bound in 
the animal that was injected with 32 mg IgM (Table 3). Nevertheless, the 
quantities of antibody administered in the third experiment seem to be 
too small to result in detectable levels of antibody-bound progesterone, 
indicating that an immediate equilibrium is established between a low per-
centage of occupied binding sites and a relatively rapid clearance of anti-
body-bound progesterone. 
Increased plasma concentrations of total progesterone, similar to the 
ones observed in the gilts injected with 50 mg antibody or more (experiment 
1), were also found by Cheesman and Chatterton (1982) after treatment of 
rats with polyclonal antiserum against progesterone and, amongst others, 
by Wang et al. (1984), Rider and Heap (1986) and Phillips et al. (1988) 
after postcoital administration of anti-progesterone monoclonal antibodies 
in mice, ferrets and rats, respectively. Wang et al. (1984) suggested that 
a high concentration of total progesterone is maintained in circulation 
on account of the high affinity of the antibody for the steroid and that 
ovarian progesterone secretion had been stimulated by a pituitary or pla-
cental luteotrophin. Cheesman and Chatterton (1982), however, concluded 
from their experiments that progesterone levels were primarily controlled 
by binding of progesterone to the antibody rather than by stimulation of 
ovarian progesterone secretion, since the total progesterone concentration 
never exceeded the binding capacity of the circulating antibody. They sug-
gested that administration of anti-progesterone antibodies leads to a di-
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ponse in the pig compared to the rat. The anti-mouse response found in 
our experiments is in line with human clinical trials with murine mono-
clonal antibodies, in which almost all non-immunocompromised patients de-
veloped anti-mouse immunoglobulin antibodies which inhibited the therapeu-
tic effect (for references, see Cole et al., 1985). A possible strategy 
to avoid such an anti-mouse response is the use of homologous monoclonal 
antibodies. However, these may, in turn, elicit an anti-idiotype response 
that, likewise, could reduce the effects of the MCA, although Ehrlich et 
al. (1987) reported that the repeated use of human MCA in rhesus monkeys 
did not trigger any other response than a normal decay in antibody level 
in all but one animal. At our laboratory a comparative study on the use 
of homologous and heterologous monoclonal antibodies for passive immuniza-
tion is in progress. 
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Abstract 
Bovine-murine heteromyeloma cell lines were prepared by fusing lymphoid 
cells from a bovine leukemia virus-infected cow with mouse myeloma cells. 
Selection of hybrid cell colonies was based on the ratio of bovine and 
murine chromosomes, the presence of cell-surface immunoglobulins and growth 
characteristics. First generation fusion partners were compared for fusion 
efficiency and the generated number of antigen-specific antibody-producing 
clones. From first generation heteromyelomas hybrid cell colonies, which 
initially secreted antibodies, were selected to function as second gene-
ration fusion partners. Although fusion efficiencies for both generations 
did not differ, the second generation heteromyelomas yielded more speci-
fic antibody-producing clones. Fusion of heteromyelomas with either lymph 
node cells or splenocytes indicated that fusion with lymph node cells re-
sults in more specific antibody-producing clones, whereas fusion efficiency 
was found to be higher with splenocytes. The optimal time-intervals between 
the final booster injection and fusion were found to be 4 days for spleno-
cytes and 7 days for lymph node cells, respectively. Finally, the characte-
rization of bovine monoclonal antibodies against bovine rotavirus and preg-
nant mare serum gonadotrophin as well as their neutralizing capacity in 
vitro are described. 
Introduction 
In animal production monoclonal antibodies have become important tools 
in diagnostic and fundamental research. In addition, monoclonal antibo-
dies can be used to optimize physiological processes such as growth and 
reproduction and are important in the treatment of certain animal disea-
ses (Booman, 1988). A limiting factor for the use of monoclonal antibo-
dies in passive immunization might be their murine or rat origin when ap-
plied in other species. Human clinical trials with murine monoclonal anti-
bodies indicate that almost all non-immunocompromised patients developed 
anti-mouse immunoglobulin antibodies which inhibited the therapeutic effect 
(Cole et al., 1985). In pigs, repeated administration of murine antibodies 
generated a significant antibody response to mouse immunoglobulins (Arriëns 
and Booman, 1989). In addition, immunoglobulins have species-specific ef-
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fector determinants, which allow cooperative cellular effects not possible 
with heterologous antibodies (Nose and Wigzell, 1983). 
The production of antibodies other than of murine or rat origin has 
been greatly hampered, however, by the lack of suitable myeloma fusion 
partners. Nevertheless, some success has already been achieved in the de-
velopment of monoclonal antibodies from livestock species. Srikumaran et 
al. (1983/1984) demonstrated the potential of interspecies hybridomas, 
produced by fusing mouse myeloma cells with bovine lymphocytes. Such in-
terspecies fusions resulted in bovine antibodies against bovine enteric 
coronavirus (Raybould et al., 1985) as well as in antigen-specific ovine 
monoclonal antibodies (Beh et al., 1986; Groves et al., 1987b). A severe 
limitation to interspecies hybridomas, however, is their genetic instabi-
lity, due to the selective elimination of the non-murine chromosomes. In 
another approach, followed by Tucker et al. (1984; 1987), Groves et al. 
(1987a; 1988) and by us, bovine-murine hybrid myelomas (heteromyelomas) 
have been constructed in an attempt to obtain a better fusion partner for 
the production of bovine monoclonal antibodies. It was anticipated that 
a heteromyeloma would retain the superior fusion characteristics of the 
mouse myeloma cells and be better able to support stable bovine antibody 
production because of the presence of bovine chromosomes. 
The present paper reports the construction and selection of a bovine-
murine heteromyeloma cell line. In addition, the optimal interval between 
boosting and harvesting of the lymphocytes and the source of lymphocytes 
was studied to a limited extent. In this study bovine monoclonal antibodies 
have been produced against rotavirus and pregnant mare serum gonadotrophin 
(PMSG). 
Materials and Methods 
Construction and selection of 1st generation heteromyeloma cell lines 
Bovine-murine heteromyeloma cell lines were constructed by fusing lym-
phoid cells from a bovine leukemia virus (BLV)-infected cow with cells 
of the X63-Ag8.653 mouse myeloma cell line (Kearney et al., 1979). Seven 
years before, this cow was experimentally infected with BLV strain J 5 
(Ressang et al., 1974). The supposedly transformed lymphoid cells were 
98 
selected from hyalin-appearing spots of the popliteal lymph node. After 
fusion, growth characteristics like doubling time, viability after free-
zing and subsequent thawing, and homogeneity of cell type of the colonies 
of hybrid cells were determined. In addition, the ratio between numbers 
of bovine and murine chromosomes, bovine and mouse cell-surface Ig, and 
secretion of bovine Ig were assessed. Selected hybridoma colonies were 
cloned twice by limiting dilution and the subclones checked on chromosomal 
content, cell-surface Ig and growth characteristics. Subclones chosen to 
be fusion partners were made HAT-sensitive by growing them for at least 
2 months in medium supplemented with 30 /ig/ml 8-azaguanine (Sigma). Cells 
were tested at intervals for HAT-sensitivity by culturing them in HAT-me-
dium. The fusion partners were screened for the presence of BLV by proce-
dures as described below. 
Next, heteromyeloma cell lines were each fused in two consecutive expe-
riments with popliteal lymph node cells from calves immunized against rota-
virus. Heteromyeloma cell lines were selected on basis of fusion efficien-
cy, number and stability of specific anti-rotavirus bovine Ig-producing 
clones 6 weeks after fusion, as well as earlier mentioned parameters. Fu-
sion efficiency was defined as the number of colonies per 1 x 10' lympho-
cytes 3 weeks after fusion. Colonies were counted using an inverted micro-
scope . 
Comparison of 1st and 2nd generation heteromyeloma cell lines 
From foregoing fusion experiments of the 1st generation heteromyelomas 
with lymphoid cells of calves immunized against rotavirus hybrid cell colo-
nies, which initially secreted antibodies, were selected to function as 
2nd generation bovine-(bovine-murine) heteromyelomas. Cells of those colo-
nies were cloned twice and rendered HAT-sensitive. In order to compare 
the thus constructed 2nd generation of heteromyelomas with the 1st gene-
ration, fusion experiments with cells of popliteal lymph nodes of calves 
immunized against rotavirus were performed. 
Timing of fusion and source of lymphocytes 
The ultimately selected heteromyelomas were used for fusion experiments 
with both splenocytes and popliteal lymph node cells on Day 7 or Day 4 
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after the last booster injection, respectively. For these experiments cal-
ves were immunized with PMSG. 
Immunization of calves 
Male Jersey calves aged between 6 and 12 months were injected intra-
muscularly (i.m.) with 300 fig density gradient-purified bovine rotavirus 
(Dutch field isolate 26B) in complete Freund's adjuvant (CFA), followed 
by an injection of the similar dose (i.m.) in incomplete Freund's adju-
vant (IFA) 3 weeks later. About 6 weeks later and 4 days before fusion, 
calves received 300 fig rotavirus in 10 ml phosphate buffered saline (PBS) 
intravenously. The purification procedure for rotavirus was as follows: 
Rotavirus was grown on MA 104 cells. After one cycle of freezing and thaw-
ing cell debris was removed by centrifugation for 10 min at 1500 rpm. The 
supernatant was loaded on 10 ml of 45% w/v sucrose/PBS. After centrifuga-
tion for 3 h at 27,000 rpm, the pellet was suspended in 5 ml of PBS and 
centrifuged once more for 15 min at 1500 rpm to remove insoluble material. 
The supernatant was used for immunization. 
For immunization to PMSG, calves were injected five times i.m. with 
3000 IU PMSG (Intervet) and adjuvant with intervals of 4 weeks. CFA was 
used in the first injection, and IFA thereafter. Calves were boosted in-
travenously with 3000 IU PMSG in 10 ml PBS about 6 weeks after the last 
injection and 7 or 4 days before fusion. 
Fusion 
Heteromyeloma cells were maintained in Dulbecco's Modified Eagle's Me-
dium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 
penicillin, streptomycin and glutamin. Fusions between spleen or lymph 
node cells and myeloma cells were performed as previously described (Booman 
et al., 1984) with minor modifications. When in a later stage assays for 
bovine Ig and determination of Ig isotype had to be performed, hybrid cells 
were grown in DMEM with 10% horse serum. 
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ELISAS 
Detection of bovine Ig 
A double antibody sandwich assay was used for the detection of bovine 
Ig (Van Zaane and IJzerman, 1984). Briefly, microtiter plates were coated 
with a monoclonal antibody recognizing a common determinant of bovine IgG^, 
IgG2, IgA and IgM. After incubation with the culture supernatants bound 
antibody was detected using a mixture of rabbit antisera against bovine 
IgG, IgM and IgA conjugated to horse-radish peroxidase (HRP). 
Determination and quantification of bovine Ig isotypes 
In a similar type of assay, plates coated with monoclonal bovine Ig 
isotype-specific antibodies were used (Van Zaane and IJzerman, 1984) for 
the determination and quantification of bovine Ig isotypes. Two-fold dilu-
tions of bovine Ig isotype standards and culture supernatants were added 
and the assay developed as described before. The concentration of bovine 
Ig in culture supernatants was estimated from titration curves. 
Detection of anti-rotavirus bovine antibodies 
An antibody capture assay was used for detection of specific anti-rota-
virus antibody-secreting clones (Van Zaane and IJzerman, 1984). Microtiter 
plates were coated with the anti-bovine Ig monoclonal antibody. After incu-
bation with the culture supernatants, rotavirus was added and subsequently 
bound antibody was detected using swine anti-rotavirus antibodies conju-
gated to HRP. 
Detection of anti-PMSG bovine antibodies 
Screening for monoclonal antibodies directed against PMSG was performed 
by an indirect double antibody sandwich assay. Microtiter plates were 
coated with rabbit anti-PMSG antiserum (10 ^ g Ig/ml, 100 ^ il/well) . After 
blocking with 1% BSA, a standard solution of PMSG (6 IU/ml) was incubated 
for 75 min at 37°C. Then culture supernatants were incubated for 1.5 h 
at rT or overnight at 4°C and rabbit anti-bovine Ig(G,M,A) conjugated to 
HRP (Nordic Immunological Laboratories) was used as a conjugate. Detailed 
procedures are similar as for the ELISA described earlier (Booman et al., 
1984). 
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BLV screening 
Cell suspensions of the first generation heteromyeloma cell lines were 
screened for the presence of BLV by a double antibody sandwich assay using 
monoclonal antibodies directed against two different BLV-p24 antigenic 
determinants (De Boer et al., 1987). A semi-purified BLV preparation was 
used as positive control. The heteromyelomas were also tested for the pre-
sence of BLV by intraperitoneal inoculation of 5x10° cells in four 6 month-
old male Flevolander lambs, of which serum samples were collected in four-
weekly intervals over a six months period. The serum samples were tested 
for anti-BLV antibodies by an agar gel precipitation test and a complex-
trapping-blocking ELISA-p24 (De Boer et al., 1987). 
Immunofluorescent staining of cell-surface immunoglobulins 
The presence of bovine and murine surface immunoglobulins was detected 
by direct immunofluorescence tests. Cells were incubated (30 min on mel-
ting ice) with fluorescein-conjugated rabbit anti-bovine Ig F(ab')2 frag-
ments for the detection of cell-surface bovine Ig and with a rabbit anti-
mouse Ig conjugate to detect murine Ig. After washing, fluorescence of 
cells was examined on a microscope slide under a phase contrast UV micro-
scope . 
Karyotyping 
Chromosome preparations were made following standard procedures. The 
chromosomes were examined after application of the GTG-banding technique 
as described by Hageltorn and Gustavsson (1973). For each cell line to 
be karyotyped, the total chromosome number and the number of bovine chro-
mosomes were determined on five individual cells. Bovine chromosomes were 
differentiated from the mouse chromosomes on basis of their negatively 
stained centromeric regions (Lin et al., 1977). 
Characterization of anti-rotavirus and anti-PMSG bovine monoclonal anti-
bodies 
To study the reactivity of anti-rotavirus monoclonal antibodies against 
double-shelled rotavirus of bovine, porcine and/or human origin, one mono-
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clonal antibody was further characterized by immunogold electronmicroscopy 
(Vreeswijk et al., 1988). Briefly, rotavirus was absorbed onto Ni-collodion 
carbon-coated grids and incubated with monoclonal antibody in PBS for 
2 h at 37°C. After washing, bound monoclonal antibody was detected follow-
ing incubation with 1 j»g Protein A/ml PBS (30 min at rT) and subsequently 
with rabbit anti-Protein A Ig (Sigma), conjugated to colloidal gold (30 
min at rT). Some rotavirus-coated grids were floated on a drop of 0.5% 
glutaraldehyde in PBS for 1 min before the incubation with the monoclonal 
antibody was carried out. The strains used were bovine rotavirus RA174, 
purified from a pool of faeces from calves on different farms, porcine 
rotavirus strain of Pensaert, number 277, probably subtype 1, serotype 
4, and finally with human rotavirus, a sample of a child with severe diar-
rhoea. 
The neutralizing capacity of the anti-rotavirus monoclonal antibody 
was determined by Dr. P.P. Pastoret, Université de Liège, Bruxelles 
(Thiriart et al., 1987), using bovine rotavirus strain 81/36F (Castrucci 
et al., 1983). 
The cross-reactivity of a bovine anti-PMSG monoclonal antibody with 
bovine LH and FSH was determined by indirect double antibody sandwich 
ELISAS (Booman et al., in preparation). The in vitro neutralizing capacity 
of the monoclonal antibody was determined in a validated assay (M.J.H. 
Hoeijmakers, Intervet Int. B.V., Boxmeer). Standard solution PMSG was pre-
incubated with the antibody and the mixture was tested for residual PMSG 
by a double antibody sandwich ELISA. In this assay a mouse monoclonal anti-
body against PMSG was used for coating and rabbit anti-PMSG-HRP as a conju-
gate. 
Results 
Construction and selection of 1st generation heteromyeloma cell lines 
Fusion of lymphoid cells from a BLV-infected cow with cells of X63-
Ag8.653 resulted in 32 growing hybrid colonies after 6-8 weeks of culture. 
The hybrid cells contained variable numbers of chromosomes, ranging between 
53 and 112 with a mean of 67.6 ± 12.6. The percentage of bovine chromo-
somes ranged between 0 and 29 with a mean of 14.8 ± 8.4. Only two hybridoma 
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colonies were positive for bovine cell-surface Ig (1 II and 3 V) and were 
secreting bovine IgM. Mouse cell-surface Ig was not detected. 
On basis of their Ig production, 1 II and 3 V were selected for use 
as the 1st generation heteromyeloma fusion partners together with 2 hybrids 
(3 XIV and 1 XXIII) with a high content of bovine chromosomes and favor-
able growth characteristics. 3 V also contained a high number of bovine 
chromosomes. No BLV in cell suspensions of 1st generation fusion partners 
or BLV-specific antibody in serum samples of inoculated lambs could be 
detected. 
Fusion of the 1st generation fusion partners with lymph node cells from 
calves immunized with rotavirus, resulted in large differences in numbers 
of hybrid colonies generated by 1 II and 3 V on one hand and 3 XIV and 
1 XXIII on the other. The latter two cell lines showed negligible low fu-
sion efficiencies and therefore appeared not to be useful as fusion part-
ners. Although the fusion efficiency of 1 II and 3 V was relatively high 
(42 and 70, respectively), only 2 hybridomas per fusion partner produced 
anti-rotavirus antibodies for more than 6 weeks. Three out of these 4 anti-
rotavirus antibody-producing cell lines secreted a mixture of IgM and IgG^ 
and one cell line secreted only IgG^. With regard to the total number of 
hybrid colonies generated after fusion with 1 II and 3 V about 20 and 50%, 
respectively, produced bovine Ig. About 70% of these bovine Ig-producing 
hybridomas secreted IgM, 20% IgM + IgG^ and 10% IgG^. When karyotyping 
a group of bovine Ig-producing hybridomas (n = 15), the total number of 
chromosomes ranged between 68 and 154 with a mean of 111.2 ± 24.9. The 
percentage of bovine chromosomes varied between 11.6 and 36.5 with a mean 
of 26.2 ± 4.4. 
Comparison of 1st and 2nd generation heteromyeloma cell lines 
The hybridoma colonies 13 XIII and 33 VI, generated in fusion experi-
ments with 1 II and 3 V, respectively, were chosen as 2nd generation fusion 
partners. Both hybridomas secreted anti-rotavirus antibodies for the first 
3-4 weeks after fusion, but subsequently lost this activity. They did not 
secrete unrelated bovine Ig either. In Table 1 characteristics of 13 XIII 
and 33 VI are compared with characteristics of the 1st generation fusion 
partners 1 II and 3 V. 
In Table 2 results of the fusion experiments of the selected 1st and 
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the 2nd generation fusion partners with lymph node cells from calves immu-
nized against rotavirus are summarized. No difference in fusion efficiency-
was observed between the first generation heteromyelomas and their second 
generation dérivâtes. However, the number of specific anti-rotavirus anti-
body-producing hybridomas was higher with the 2nd generation fusion part-
ners. For this reason and since 13 XIII and 33 VI are non-secretors, these 
cell lines were preferable to 1 II and 3 V as fusion partners. In the case 
of the 2nd generation heteromyelomas fusion efficiency of 33 VI was higher 
than of 13 XIII, but the number of specific antibody-producing hybridomas 
was about the same. Consequently, subsequent experiments were performed 
with the two 2nd generation heteromyeloma cell lines. 
From 5 antigen-specific antibody-producing hybrid colonies generated 
from 13 XIII and 33 VI, the total number of chromosomes ranged between 
113 to 162 with a mean of 137.8 ± 17.4. The percentage of bovine chromo-
somes varied between 26 and 31 with a mean of 27.9 ± 1.9. Table 3 summa-
rizes the karyotyping results of hybrid cells after fusion of X63-Ag8.653 
with lymphoid cells of the BLV-injected cow and after fusions of bovine 
lymphocytes with the 1st and 2nd generation fusion partners. 
Timing of fusion and source of lymphocytes 
Results of fusion experiments of 2nd generation fusion partners 13 XIII 
and 33 VI with spleen and popliteal lymph node cells on Day 4 or Day 7 
after the final intravenous booster injection are summarized in Table 4. 
It can be concluded that the fusion efficiency of the heteromyeloma cell 
lines with lymph node cells was considerable lower than with spleen cells; 
the number of specific antibody-producing hybridomas, however, was much 
higher with the lymph node cells. 
Fusion with lymph node cells on Day 4 resulted in a higher fusion effi-
ciency than fusion on Day 7. For antigen-specific antibody-producing hybri-
domas, however, fusion on Day 7 was preferable. In contrast, fusion with 
spleen cells resulted only on Day 4 in specific antibodies, while fusion 
efficiencies were about equal on Day 4 and 7. 
Comparing the fusion partners, 33 VI showed a higher fusion efficiency 
with lymph node cells than 13 XIII. The number of specific antibody-pro-
ducing hybridomas generated from 33 VI was, however, lower both with lymph 
node and spleen cells. The best combination appeared to be fusion of 13 
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XIII with lymph node cells on Day 7. 
Characterization of specific bovine monoclonal antibodies 
Anti-rotavirus antibody 
One of the anti-rotavirus antibody-producing hybrid colonies (12 XX), 
generated by fusion of 1 II with stimulated lymph node cells, was further 
characterized. The total number of chromosomes before cloning was 120, 
of which 22 (18%) were of bovine origin. After cloning cells contained 
109 chromosomes including 17 (16%) of bovine origin. Before cloning the 
hybrid cells of 12 XX secreted immunoglobulins of IgM + IgG^ class, after-
wards IgGi only. The concentration of bovine IgG^ in supernatant was about 
10 Mg/ral per 2.5 x 105 cells/48 h. The hybridoma cell line has been active-
ly secreting in culture for more than six months. The doubling time (2 
x 10-3 cells, 10% FCS) was about 26 h. In immuno-electronmicroscopy prepa-
rations of untreated and glutaraldehyde-treated bovine rotavirus two dis-
tinct types of virus particles could be recognized: labelled (Fig. 1A,C) 
and unlabelled (Fig. IB) particles. The unlabelled particles were easily 
identified as single-shelled rotaviruses. Labelled particles in unfixed 
preparations showed a fuzzy outline (Fig. 1A), while sometimes goldpar-
ticles appeared to have drifted away from the characteristic rotavirus 
•*'" -\;ds^ ' J 
-& . 
Figs. 1. Colloidal gold immuno-electronmicroscopy carried out directly 
(Fig. 1A,B) or after fixation (Fig. 1C) on virus particles of bovine rota-
virus. Single-shelled virus particles did not show a reaction with the 
monoclonal antibody (Fig. IB, ss). After application of a fixation proce-
dure before immunoreactions were carried out, the labelled particles could 
easily be identified as double-shelled particles (Fig. IC, ds; arrow, outer 
shell). Similar results were obtained with swine and human rotaviruses. 
Bar in (A) indicates 50 nm. 
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backbone (Fig. IA, arrowheads). After the application of glutaraldehyde 
fixation we found gold particles bound to the intact outer shell of double-
shelled particles (Fig. IC, ds; arrow, outer shell). Similar results were 
obtained with swine and human rotavirus (not shown). In the in vitro neu-
tralization assay according to Thiriart et al. (1987) the antibody did 
not neutralize bovine rotavirus (strain 81/36 F). 
Anti-PMSG antibody 
4 XII is a hybrid cell line generated by fusion of 33 VI with stimu-
lated lymph node cells. The total number of chromosomes after cloning was 
156, of which 42 (27%) were of bovine origin (no data are available of 
chromosome content before cloning). The cells of hybridoma cell line 
4 XII secreted antibodies of the IgG]^ subclass at a level of 10 - 15 fig 
per 2.5 x 105 cells/48 h. The cell line has been actively secreting in 
culture for more than six months. Doubling time was about 29 h. The anti-
bodies did not show cross-reactivity with bovine FSH and LH. The in vitro 
neutralizing capacity of this antibody, present in 10 times concentrated 
serum-free supernatant (2.5 x 105 cells/48 h) , was 550 IU PMSG/ml. Cells 
were easily adapted to growth in serum-free medium (HB 102; HANA Media). 
Discussion 
Fusion of lymph node cells of a BLV-infected cow with murine myeloma 
cells resulted in hybrid colonies with a high variability in number of 
bovine chromosomes. From the observation that two hybrid cell lines re-
tained cell-surface Ig from the parent BLV-cells and secreted bovine IgM, 
it was reasoned that they would be able to support stable bovine antibody 
production after fusion with stimulated bovine B-lymphocytes. Although 
the number of cell lines secreting antigen-specific antibodies was low, 
this expectation has been confirmed. Whether two additional non-secreting 
hybrid cell lines, that had been selected as fusion partners only based 
on a relatively high number of bovine chromosomes and favorable growth 
characteristics, would also sustain secretion of immunoglobulins, could 
not be evaluated, as the fusion efficiency of both latter heteromyelomas 
was rather negligible. The results of the karyotypic analysis of the four 
first generation heteromyelomas suggest that there is no direct relation-
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ship between the number of bovine chromosomes and characteristics important 
for the selection of the first generation fusion partners. This was like-
wise reported by Murphy et al. (1986) in human monoclonal antibody product-
ion. The few bovine chromosomes present in the cells of heteromyeloma 
1 II are apparently sufficient to support endogenous Ig production as well 
as the generation of stable hybridomas that secrete relatively high yields 
of bovine Ig. Yarmush et al. (1980) reported that they could not detect 
any rabbit chromosomes in rabbit-mouse interspecies hybridomas secreting 
rabbit immunoglobulins and presented evidence for translocation of the 
relevant rabbit genes to a mouse chromosome. On the other hand, there seems 
to be a correlation between bovine chromosome content and bovine Ig pro-
duction, since the higher number of bovine chromosomes present in 3 V com-
pared to 1 II corresponds to the percentages of hybrid Ig-secreting cell 
lines (50 and 20 percent, respectively). Hybrid cell colonies generated 
by fusion of the first generation fusion partners retained much more bovine 
chromosomes than the cell colonies produced by fusion of the mouse myelo-
ma cells with the lymph node cells of the BLV-positive cow. 
It was expected that the second generation non-secreting heteromyelomas 
would still have the apparatus for support of immunoglobulin secretion 
and would generate a higher yield of antibody-producing cell lines. Indeed, 
substantially more antigen-specific antibody-producing lines were obtained 
with the second generation than with the first generation fusion partners. 
This cannot simply be ascribed to differences in bovine chromosomal numbers 
(see 3 V and 33 VI and their fusion products). The number of bovine chromo-
somes in 1 II and 13 XIII was indeed different, but in the fusion products 
of both heteromyelomas this difference had largely disappeared. For that 
matter, Tucker et al. (1987), using the same approach, found an increase 
in the retention of bovine chromosomes in 2nd generation fusion partners 
compared with 1st generation fusion partners and an increase in number 
of antigen-specific clones. On average, fusion of the 2nd generation fu-
sion partners with bovine B-lymphocytes resulted in an increase in the 
absolute number of bovine chromosomes, while the relative number tended 
to rise to a certain limit. There was considerably less variability in 
chromosomal number. Apparently, the number of bovine chromosomes has an 
upper limit. In human-mouse heterohybrids a similar threshold seems to 
be observed. Hybrids usually have maximally five times more mouse than 
human chromosomes (Raison et al., 1982; Teng et al., 1985). Whether a third 
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generation bovine-murine heteromyeloma cell line is beneficial to improve 
the levels of antibody secretion and to ensure that high levels of secre-
tion are sustained, is currently being explored. 
For each of the selected 1st and 2nd generation fusion partners many 
more antigen-specific immunoglobulin-producing clones could be detected 
in the first weeks after fusion (data not shown). However, in general their 
secretion level was very low and within 6 weeks they lost their activity. 
The numbers of this type of colony were about twice as high as in the 
mouse-mouse system. A similar limitation occurs in human monoclonal anti-
body production, generally attributed to either overgrowth by non-secreting 
lymphocyte 'contaminants' or to the loss of structural genes coding for 
immunoglobulin. As suggested by James and Bell (1987), other factors in-
clude deficits in growth and differentiation factors and their receptors, 
structural and regulatory gene defects and imperfections in the synthetic 
and secretory machinery of the cells. 
Our experiments indicate that the fusion efficiency is higher with sple-
nocytes than with lymph node cells. However, the number of antigen-specific 
antibody-secreting clones was lower in the case of splenocytes, notwith-
standing the intravenous route for the final booster which preferentially 
stimulates splenocytes. Apart from our work no comparative studies of this 
nature have been published in the area of bovine monoclonal antibody pro-
duction. In contrast to human monoclonal antibody technology, where no 
differences between spleen and lymph node fusions were found (Jahn et al., 
1988), in the mouse fusion of popliteal and inguinal lymph node lympho-
cytes also induced a higher fusion efficiency as well as a higher frequency 
of hybridomas secreting specific antibody than fusion with splenocytes 
(Mirza et al., 1987). 
As in murine and human antibody production (for references, see James 
and Bell, 1987), we found that in cattle the preferred interval between 
the final booster injection and fusion of splenocytes is 3-4 days. The 
optimal time for the lymph node cells seems somewhat later. Additional 
immunocytochemical data from our laboratory (Wissink et al., 1989) show 
that the appearance of plasma cells in medullary cords of peripheral lymph 
nodes takes place 4-5*s days after the final booster injection. 
Further studies on one of the anti-rotavirus and anti-PMSG monoclonal 
antibodies proved the usefulness of the heteromyelomas for the production 
of bovine monoclonal antibodies. Both antibody-producing cell lines showed 
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good cloning efficiency (about 30%), cells can grow in a minimal medium 
even under serum-free conditions and secretion levels obtained are rela-
tively high in comparison with other reports in bovine (Tucker et al., 
1984; Groves et al., 1987a) as well as in human monoclonal antibody pro-
duction (for references, see Kozbor and Croce, 1985). In addition, prelimi-
nary results from our laboratory indicate that it is possible to obtain 
bovine monoclonal antibodies via ascites production or high serum titers 
in irradiated (300 rad), pristane-treated calves by inoculation of at least 
Q 
1 x 10 hybrid cells (data not shown). Although the anti-rotavirus antibody 
was directed against an outer capsid glycoprotein, which might theoreti-
cally carry antigenic sites for virus neutralization, the antibody did 
not neutralize bovine rotavirus in vitro. The in vitro neutralizing capa-
city of the anti-PMSG monoclonal antibody was very potent. Further studies 
on the in vivo neutralizing capacity of this antibody are currently in 
process. Since a murine anti-PMSG monoclonal antibody has recently become 
available commercially (Neutra-PMSG, Intervet), a comparative study of 
the inhibitory capacity and the efficacy of the bovine and murine anti-
bodies after repeated treatment is now possible. 
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Abstract 
In the present experiments the efficacy of murine and bovine monoclonal 
antibodies for passive immunization in cattle was compared. The in vivo 
immunoneutralization of pregnant mare serum gonadotrophin (PMSG) by murine 
and bovine antibodies after repeated administration was chosen as a model 
for this study. Results indicate that repeated injections of murine mono-
clonal antibodies against PMSG (mMCA) alone did not, or only to a small 
degree, elicit an anti-mouse immune response. The simultaneous administra-
tion of mMCA and PMSG resulted in relatively high levels of anti-mouse 
antibodies after the second injection, leading to a decrease in neutrali-
zing activity of mMCA. The results suggest that the neutralizing activity 
of mMCA is inhibited more by anti-idiotypic than by anti-isotypic antibo-
dies against mMCA. In vivo, the bovine monoclonal antibody against PMSG 
(bMCA) only partially neutralizes PMSG. After repeated administration of 
bMCA, either alone or in combination with PMSG, no anti-bMCA antibodies 
could be detected in our assay system. In addition, no change in plasma 
levels of bMCA and PMSG compared with levels after the first injection 
was observed. Although it has to be confirmed by further experiments 
whether our findings can be generalized, the present results suggest that 
for repeated passive immunization in cattle homologous antibodies are to 
be preferred above heterologous antibodies. 
Introduction 
In animal production monoclonal antibodies are increasingly finding 
application in the area of passive immunization, for example in the immuno-
modulation of reproductive processes (Booman, 1988). A limiting factor 
for the use of monoclonal antibodies in passive immunization when applied 
in other species might be their murine or rat origin. Human clinical trials 
with murine monoclonal antibodies indicate that almost all non-immunocom-
promised patients develop anti-mouse immunoglobulin antibodies which inhi-
bit the therapeutic effect (Cole et al., 1985). In pigs, for instance, 
a significant antibody response to mouse immunoglobulins is generated after 
repeated administration of murine antibodies (Booman et al., 1989a). The 
immune response may be directed partially against the isotypic determi-
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nants, partially against the idiotypic determinants of the antibodies admi-
nistered (Schroff et al., 1985; Shawler et al., 1985). In addition, hetero-
logous immunoglobulins lack species-specific effector determinants which 
are necessary for cooperative cellular effects (Nose and Wigzell, 1983). 
Although anti-idiotypic responses cannot be excluded as a complicating 
factor, homologous antibodies might offer some advantages over their murine 
counterparts in terms of effectiveness for passive immunization. At our 
laboratory a bovine-murine heteromyeloma cell line for the production of 
bovine monoclonal antibodies has been constructed (Booman et al., 1989b), 
which offers the possibility to compare the efficacy of bovine and murine 
antibodies after repeated administration to cattle. The neutralization 
of simultaneously administered pregnant mare serum gonadotrophin (PMSG) 
was chosen as a model for such a study. PMSG is used in cattle embryo 
transfer programmes to induce superovulation. The prolonged presence of 
the exogenous gonadotrophin may cause adverse effects, leading to a rela-
tively high percentage of embryos of poor quality. To prevent the prolonged 
action of PMSG, antibodies against the gonadotrophin are administered to 
superovulated cattle immediately after insemination. These antibodies neu-
tralize the residual PMSG in circulation and, consequently, the number 
of embryos of good quality may increase (Dieleman et al., 1989). 
Materials and Methods 
Animals 
Twelve Holstein Friesian x Dutch Friesian heifers with normal oestrous 
cycles were kept on a slatted floor in a loose housing system. All ani-
mals were 14 months old and weighed + 300 kg at the beginning of the expe-
riments. Before the experiments started, oestrus was synchronized by Syncro 
Mate-B (Intervet). The day an animal came into oestrus was defined as D . 
Antibodies 
Neutra-PMSG (Intervet), a commercially available monoclonal antibody 
preparation against PMSG, served as a source for murine monoclonal anti-
bodies (mMCA). One vial of Neutra-PMSG contained 5 ml of solution with 
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a concentration of 200 /ig IgG^/ml, which neutralizes residual circulating 
PMSG in cows, 3 to 5 days after administration of up to 3000 IU PMSG. 
Bovine monoclonal antibodies against PMSG (bMCA) were produced by hybri-
doma cell line 4 XII (IgG^), obtained by fusion of bovine-murine hetero-
myeloma cells with stimulated lymph node cells of calves (Booman et al., 
1989b). Cells were cultured on serum-free cell culture medium (HB 102; 
HANA Media). The supernatant was concentrated tenfold on an XM-50 Diaflo 
membrane (Amicon Corp.). Two different batches of culture supernatant with 
a concentration of 80 and 120 pg IgG]^/ml were used for in vivo neutraliza-
tion experiments. The in vitro neutralizing capacities of both batches 
of bMCA, determined by procedures described below, were 4.8 and 4.2 IU 
PMSG/jjg, respectively. 
As a control a bovine polyclonal antiserum against PMSG (bPCA) was pro-
duced by injecting 2 heifers intramuscularly with 3000 IU PMSG (Folligonan; 
Intervet), emulsified in complete (first injection) or incomplete Freund's 
adjuvant at 5 four-weekly intervals. Heifers were boosted intravenously 
with 5000 IU PMSG in PBS 8 weeks after the last injection and were slaugh-
tered four days later. For serum production blood was allowed to clot at 
37°C for one h and subsequently at 4°C for 6 h. The serum, separated by 
centrifugation at 1600g for 10 min at 4°C, was pooled and stored at 
-80°C. The in vitro neutralizing capacity of the bPCA was 1000 IU PMSG/ml. 
In the present experiments heifers were injected with 3000 IU PMSG. 
The amount of mMCA per injection was 5 ml of Neutra-PMSG (1 mg IgG^). The 
neutralizing capacity of Neutra-PMSG is lower in vivo than in vitro (data 
Intervet). As this might also be the case for bMCA, the amount of bMCA 
used in the in vivo experiments was determined as the quantity that could 
neutralize 6000 IU PMSG in vitro (6 ml of bPCA). However, because of in-
correct determination of the in vitro neutralization capacity of bMCA, 
in vivo experiments with bMCA were in fact performed with 1 or 1.8 mg of 
bMCA, estimated to neutralize 4200 and 8550 IU PMSG, respectively. 
None of the antibodies used in this study did cross-react with bovine 
FSH and LH in vitro, as determined by the procedures described below. 
Experimental design and blood sampling 
Six groups of two heifers were treated on Day 11 + 1 of the first oes-
trous cycle after synchronization according to the following scheme : 
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mMCA group: injected with murine monoclonal antibody (heifers 12 and 13); 
mMCA+PMSG group: injected with mMCA plus 3000 IU PMSG (heifers 2 and 6); 
bMCA group: injected with bovine monoclonal antibody (heifers 26 and 29); 
bMCA+PMSG group: injected with bMCA plus 3000 IU PMSG (heifers 25 and 28); 
bPCA group: injected with bovine polyclonal antiserum (heifers 14 and 15); 
bPCA+PMSG group: injected with bPCA plus 3000 IU PMSG (heifers 16 and 23). 
Fourty-eight h after administration of the antibodies (and PMSG) each ani-
mal received 2 ml of a prostaglandin F2a analogue (Prosolvin; Intervet) 
in order to induce oestrus 48-72 h later. Between D and D.., of the second 
cycle the number of ovulations was determined by rectal palpation of the 
ovaries. On D , of the second cycle each animal received another 2 ml of 
Prosolvin to induce the third oestrus. The period between the very first 
D.. and the third D- was defined as one complete experimental period. A 
second and third experimental period followed according to the same treat-
ment schedules for the respective groups. The interval between injections 
was about 35 days. 
The first time animals from the bMCA group and heifer 25 from the bMCA 
+ PMSG group were injected with the larger dose of bMCA (1.8 mg). Anti-
bodies were injected intravenously into the jugular vein. PMSG and Pro-
solvin were injected intramuscularly. 
Blood samples were collected from the heifers treated with mMCA and 
bMCA alone or in combination with PMSG each day of the experimental periods 
between 6.00 and 8.00 h. On the day of injection with antibodies (plus 
PMSG) samples were also collected immediately after injection at 9.00 h 
and subsequently at 11.00, 17.00 and 21.00 h. On the first two days after 
injection a blood sample was taken between 16.00 and 18.00 h, in addition 
to the daily sample. 
Blood samples were collected from the jugular vein in heparinized vacu-
tainer tubes (Venoject; Terumo) and chilled immediately on ice. Plasma, 
separated by centrifugation at 1600g for 10 min at 4°C, was stored at 
-20°C. 
When oestrus was not observed, levels of progesterone were checked in 
selected plasma samples in order to test reproductive activity. 
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Enzyme immunoassays 
For all enzyme immunoassays described below, detailed assay procedures 
were similar to those described earlier (Booman et al., 1984), unless men-
tioned otherwise. 
Determination of in vitro neutralization of PMSG 
The in vitro neutralizing capacity of the monoclonal antibody prepara-
tions was determined in a validated assay by Intervet Int. (The Nether-
lands) . Equal quantities of standard solution of PMSG (0-4 IU/ml) and anti-
bodies or control serum in different dilutions were preincubated at 4°C 
and the mixture was tested for residual PMSG in a double antibody sand-
wich enzyme immunoassay. In this assay a mouse monoclonal antibody against 
PMSG (Intervet) was used for coating and rabbit anti-PMSG coupled to horse-
radish peroxidase (HRP) as a conjugate. 
Cross-reactivity with bovine LH and FSH 
Cross-reactivity of antibody preparations with bovine LH and FSH was 
determined in indirect double antibody sandwich assays. For the LH assay, 
microtiter plates were coated with rabbit anti-bovine LH (bLH) (10 /jg 
Ig/ml, 100 /il/well) . After blocking with 1% BSA, wells were incubated with 
10 ng bLH for 75 min at 37°C. The antibody preparations were incubated 
for 1.5 h at rT and rabbit anti-bovine Ig(G,M,A)-HRP or rabbit anti-mouse 
Ig-HRP (Nordic Immunological Laboratories) were used as conjugates. Cha-
racterization of rabbit anti-bLH and bLH has been described by Dieleman 
et al. (1983). The assay for FSH was similar to that for LH, except that 
rabbit anti-bFSH (UCB Bioproducts; Belgium) was used as the first anti-
body and bFSH (bFSH-B-1; USDA Animal Hormone Program) instead of bLH. 
Circulating antibody capable of binding PMSG 
In order to monitor the levels of circulating antibody still capable 
of binding PMSG an indirect double antibody sandwich assay was performed. 
Microtiter plates were coated with rabbit anti-PMSG antiserum (10 ßg Ig/ml, 
100 /il/veil) . After blocking with 1% BSA, a standard solution of PMSG (6 
IU/ml) was incubated for 1.5 h at 37°C. Then plasma samples were incubated 
for 2 h at rT or overnight at 4°C and rabbit anti-mouse Ig-HRP was used 
as a conjugate to determine levels of mMCA and rabbit anti-bovine Ig-HRP 
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for levels of bMCA. 
Significant increases in plasma levels of mMCA and bMCA were defined 
as all values higher than the average background value plus twice the stan-
dard deviation of all samples from the same heifer taken before first in-
jection. 
Circulating PMSG able to be bound by antibody 
The levels of PHSG still able to be bound by antibody were monitored 
by coating microtiter plates with the respective mMCA and bMCA (10 pg 
IgG^/ml, 100 /il/well) . After blocking, plasma samples were incubated for 
2 h at rT or overnight at 4°C and bound PMSG was detected using rabbit 
anti-PMSG antibodies conjugated to HRP. Significant increases in PMSG le-
vels were defined as for mMCA and bMCA. 
Determination and quantification of anti-mMCA and anti-bMCA immune res-
ponse 
bMCA were purified by ammonium sulphate precipitation, followed by gel 
filtration on a Sephacel HS-200 column (Pharmacia). Purity and molecular 
weight were checked by SDS-PAGE (Laemmli, 1970) or HPLC. mMCA and an irre-
levant mouse monoclonal antibody directed against human chorionic gonado-
trophs (hCG), with the same isotype (IgG^) and the same type of light 
chain ( K ) , were kindly provided in purified form by Intervet and Diosynth 
(The Netherlands), respectively. Biotinylation of purified antibodies was 
performed as described by Wagener et al. (1984). Antibody preparations 
were stored at -80°C in 50% glycerin. 
For determination of anti-mMCA antibodies, purified mMCA or anti-hCG 
(2 /ig/ml; 100 /xl/well) were absorbed onto microtiter plates. After block-
ing with 0.5% gelatin in PBS for 30 min at 37°C, plasma samples of hei-
fers treated with mMCA (either with or without PMSG) were incubated in 
mMCA- and anti-hCG-coated plates for 1 h at 37°C. Affinity-purified rabbit 
anti-mouse IgG^ antibodies (Miles) in preimmune bovine plasma (5000 - 20 
ng/ml) were included in each plate as a standard. 
For determination of anti-bMCA antibodies, plasma samples of animals 
treated with bMCA (either with or without PMSG) were diluted in a buffer 
containing a high percentage of salt (0.5M NaCl, 15mM NaßPO^121^0, 0.05% 
w/v Tween 80, pH 7.2) and incubated in bMCA-coated wells (5 /Jg/ml ; 100 
/il/well) . In this assay, serial dilutions of protein A-purified rabbit 
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anti-bovine IgG^ (Nordic Immunological Laboratories) in PBS (40 - 2 /ig/ml) , 
supplemented with 20 mg rabbit serum Ig/ml and 33 mg ovalbumin/ml, were 
used as a standard. Both anti-mMCA and anti-bMCA plates were subsequently 
incubated (1 h at 37°C) with the appropriate biotinylated antibodies dilu-
ted 1:1600 (mMCA and anti-hCG) or 1:800 (bMCA) in assay buffer (0.04M PBS, 
0.1% BSA). Finally, bound biotinylated antibodies were detected by incu-
bation with streptavidin-HRP (Amersham), diluted 1:5000 in assay buffer 
with 1% porcine serum, for 45 min at rT. Linear regression was used to 
quantify anti-MCA antibodies in plasma samples. The detection limits of 
the assays were 50 ng/ml (mMCA) and 500 ng/ml (anti-hCG and bMCA). 
Other assays 
Determination and quantification of bovine Ig-isotypes was performed 
by a double antibody sandwich assay as described by Van Zaane and IJzerman 
(1984). 
Progesterone levels in plasma samples were determined by a competitive 
assay (Van de Wiel and Koops, 1986). 
Results 
In vivo neutralizing capacity of anti-PHSG antibodies 
The in vivo neutralizing capacity of the anti-PMSG antibodies was moni-
tored by rectal palpation of the ovaries of the injected heifers. Relevant 
results are presented in Table 1. No influence on the number of ovulations, 
counted as corpora lutea (CL), was observed in the heifers treated with 
the antibodies only. One CL could be detected in 5 out of 6 animals in 
nearly all experimental periods. Heifer 29 from the bMCA group differed 
in that no CL or follicle was felt during palpation after the first treat-
ment. Exceptionally, in mMCA-treated heifer 12 two CL were present conti-
nuous ly. 
The simultaneous administration of antibody and PMSG resulted in an 
increase of the number of ovulations as treatment proceeded in the heifers 
from the mMCA + PMSG group. One CL could consequently be detected in the 
two bPCA plus PMSG-treated heifers. In heifers of the bMCA + PMSG group 
highly stimulated ovaries were found in 3 out of 6 cases. It appeared that 
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the in vivo neutralizing capacity of bPCA remained unchanged, whereas the 
efficacy of mMCA decreased after repeated administration. Finally, bMCA 
were not able to inhibit PMSG-activity in vivo in all cases. 
Levels of mMCA and bMCA capable of binding PMSG 
Levels of mMCA capable of binding PMSG in plasma of mMCA-treated heifer 
12 were increased significantly after each injection (Fig. 1). In heifer 
13 from the mMCA group, the increase in mMCA level was less obvious after 
the second injection and almost absent after the third (Table 1). 
Fig. 1 shows that on some occasions antibody levels were elevated in be-
tween the injections. 
Compared to the mMCA group, injection with mMCA plus PMSG resulted in 
a less pronounced increase in mMCA levels after the first injection. The 
observed increase in mMCA levels directly after injection was partly abo-
lished after repeated treatment (Fig. 2; Table 1). 
When bMCA were administered, a small increase in plasma levels of bMCA 
capable of binding PMSG could be observed after each injection. In animals 
from the bMCA + PMSG group the levels of bMCA were elevated only after 
the second injection in heifer 28 (Table 1). As with mMCA levels in the 
mMCA group, bMCA levels were sometimes elevated in between the injections 
(Fig. 3). Similar patterns of plasma MCA levels were observed in pigs in-
jected with different amounts of mMCA (unpublished results). 
Levels of PMSG able to be bound by antibody 
Plasma levels of PMSG able to be bound by antibody in heifers from the 
mMCA + PMSG group remained at the baseline after the first injection (Fig. 
2). Distinct PMSG peaks were, however, observed after the second and third 
injection (heifer 6; Fig. 2) or after the third injection only (heifer 2; 
Table 1). 
When animals were injected with bMCA + PMSG, a similar, although mo-
derate, elevation of PMSG levels was observed after each injection in hei-
fer 25 (Fig. 3), whereas in heifer 28 PMSG levels were moderately increas-
ed after the first injection and very strongly after the second one. After 
the third injection a very slight increase was observed in this heifer 
(Table 1). 
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TABLE 1 
Effect of administration of mMCA and bMCA either alone or together with PMSG 
on plasma levels of mMCA and bMCA capable of binding PMSG, PMSG able to be 
bound by antibody and of anti-mMCA and anti-bMCA antibodies and on number of 
corpora lutea in different experimental periods. 
Group 
No. heifer 
mMCA/bMCAa 
PMSG3 
anti-mMCA/bMCAa 
corpora lutea 
period 
period 
period 
period 
1 
2 
3 
1 
2 
3 
1 
2 
3 
1 
2 
3 
mMCA 
12 13 
++ 
++ 
++ 
-
-
-
2 
2 
2 
++ 
+ 
+/-
-
+/-
+ 
1 
2 
1 
mMCA 
2 
+ 
+ 
-
+ 
-
++ 
++ 
1 
1 
2 
+ PMSG 
6 
+ 
+/-
-
++ 
++ 
-
c 
++ 
++ 
2 
5 
4 
bMCA 
26 29 
+ 
+ 
+ 
-
-
-
1 
1 
1 
+ 
+ 
+ 
-
-
-
od 
1 
1 
bMCA + 
25 
-
-
-
+ 
+ 
+ 
-
-
-
1 
*
e 
1 
PMSG 
28 
-
+ 
-
+ 
++ 
+/-
-
-
-
*
e 
*
e 
1 
Semi-quantitative presentation of plasma levels of mMCA/bMCA, PMSG and 
anti-mMCA/bMCA: ++ relatively large increase; + a small, but significant 
(> x + 2 s.d.) increase; +/- a very small, but still significant increase; 
, - no significant increase. 
Number of corpora lutea determined by rectal palpation of the ovaries; 
in all animals of the bPCA and bPCA + PMSG groups each experimental period 
one corpus luteum was observed. 
.Largely anti-idiotypic. 
No corpus luteum or follicle was felt during palpation; based on plasma 
progesterone levels reproductively active. 
Large ovaries with many corpora lutea. 
Anti-mMCA and anti-bHCA immune response 
Repeated administration of mMCA alone (mMCA group) did not induce high 
bovine anti-mouse titers. In heifer 12 no anti-mMCA response could be de-
tected at all; in heifer 13 a slight immune response against the mMCA was 
detectable after the second injection (102 ng/ml plasma). After the third 
injection the anti-mMCA antibodies reached a level of 567 ng/ml plasma 
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heifer 12 (mMCA) 
0 12 0 0 
Days of experimental periods 
Fig. 1. Plasma l e v e l s of mMCA capable of b inding PMSG a f t e r repeated in-
j e c t i o n of mMCA. 
heifer 6 (mMCA * PMSG) 
o Ö 
< 
o 
s 
E 
10 o 0 12 0 0 
Days of experimental periods 
Fig. 2. Plasma levels of mMCA capable of binding PMSG and of PMSG able 
to be bound by antibody after repeated injection of mMCA and PMSG. 
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500 -i 
heifer 25 (bMCA + PMSG) 
0 10 0 0 
Days of experimental periods 
Fig. 3. Plasma levels of bMCA capable of binding PMSG and of PMSG able 
to be bound by antibody after repeated injection of bMCA and PMSG. 
in this heifer. To discriminate between anti-isotypic and anti-idiotypic 
antibodies, the presence of anti-isotypic (mouse IgG^ iic ) antibodies in 
plasma samples was tested in an enzyme immunoassay in which the wells were 
coated with an irrelevant monoclonal antibody. No binding to the irrelevant 
mouse monoclonal antibody was detectable. 
The humoral response of heifers from the mMCA + PMSG group was charac-
terized by a relatively strong increase in anti-mMCA antibodies shortly 
after the second injection and a further increase after the third admi-
nistration (Figs. 4 and 5). In heifer 6 (Fig. 5) a temporary drop in anti-
body titer occurred immediately after the last administration of mMCA plus 
PMSG. In the insert in Fig. 5 this phenomenon is shown in more detail. 
The nature of the anti-mouse response was largely anti-isotypic, except 
in heifer 6 after the second injection, when a predominantly anti-idiotypic 
response was observed (Fig. 5) . 
In the animals of the bMCA and bMCA + PMSG groups no anti-bMCA anti-
bodies could be detected at all. 
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100000 
10000 
1000 
heifer 2 (mMCA + PMSG) 
Days of experimental periods 
logarithmic scale 
Fig. 4 . Plasma l e v e l s of a n t i - i r r e l e v a n t murine antibody and of anti-mMCA 
an t ibod ies a f t e r repea ted i n j e c t i o n of mMCA and PMSG. 
10000 
1000 -
0 J 
anti-mMCA 
anti-irrelevant 
murine antibody 
heifer 6 (mMCA • PMSG) 
0 12 0 0 
Days of experimental periods 
'logarithmic scale 
Fig. 5. Plasma levels of anti-irrelevant murine antibody and of anti-mMCA 
antibodies after repeated injection of mMCA and PMSG. 
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Discussion 
When monoclonal antibodies are to be administered repeatedly, e.g. for 
therapeutic reasons or in order to influence physiological processes, the 
use of homologous rather than heterologous monoclonal antibodies may be 
preferred, since a humoral response against the injected xenogeneic pro-
teins may neutralize their physiological effect. The use of homologous 
monoclonal antibodies may, however, still elicit an anti-idiotypic res-
ponse . When murine monoclonal antibodies are used for tumor therapy in 
man, such an anti-idiotypic response may represent a substantial part of 
the anti-mouse antibodies present in circulation (Herlyn et al., 1986; 
Chatenoud et al., 1986; Traub et al., 1988). It is generally assumed that 
anti-idiotypic antibodies are of major clinical importance, since only 
they may abrogate the therapeutic effectiveness of the injected antibody 
(Baudrihaye et al., 1984; Chatenoud et al., 1986). 
It can be questioned, however, whether the reported anti-idiotypic res-
ponse observed when heterologous monoclonal antibodies are applied will 
occur to a similar extent when homologous antibodies are administered, 
since the formation of the anti-idiotypic antibodies may be enhanced by 
a hapten-carrier system, in which the heterologous immunoglobulin acts 
as a carrier for the idiotype, a mechanism suggested by Ehrlich et al. 
(1987). Their findings, that multiple injections of moderate amounts of 
human monoclonal antibodies in rhesus monkeys resulted in an anti-idiotypic 
response in only 1 out of 5 animals (Ehrlich et al., 1987), and that re-
peated administration of large doses (16 mg/kg) of human monoclonal anti-
bodies to rhesus monkeys failed to result in an anti-human response 
(Ehrlich et al., 1988), suggest that under the conditions usually employed 
(i.e., intravenous injection and low idiotype concentration) the idiotype 
may not be very immunogenic if the proposed carrier effect is absent. Large 
scale studies on the immunogenicity of human monoclonal antibodies in man 
have not been performed thus far, however, leaving the question unanswered 
whether repeated administration of homologous antibodies offers advantages 
compared with heterologous antibodies. 
The ability to produce bovine monoclonal antibodies in our laboratory 
enabled us to address this question in the bovine system. As a model the 
biological effectiveness and the immunogenic potential of anti-PMSG bovine 
and murine monoclonal antibodies (bMCA and mMCA, respectively) were com-
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pared in cattle. In order to determine the effectiveness of the antibodies 
administered, the in vivo PMSG-neutralizing effect was monitored in heifers 
by rectal palpation of the ovaries. As a control 2 groups of animals were 
injected with a bovine anti-PMSG polyclonal antiserum (bPCA), either alone 
or together with PMSG. One CL could be detected consistently in all heifers 
after repeated injections, indicating that the ovaries functioned normally 
and that repeated treatment did not change the efficacy of the bPCA. More-
over, when mMCA or bMCA alone were administered, no change in the number 
of CL was observed (Table 1), indicating that the experimental design did 
not influence the reproductive processes. 
In one of the two heifers injected with mMCA a more pronounced suppres-
sion in the rise of circulating mMCA levels was observed after the second 
and in particular after the third injection. This decrease in mMCA levels 
coincided with an increase in levels of anti-mouse antibodies (heifer 13; 
Table 1). In the other heifer injected with mMCA no such effect was ob-
served (heifer 12; Table 1). whether the anti-mouse response was directed 
against the idiotypic part or against the isotypic part of the mMCA could 
not be clarified because of the relatively high detection limit of the 
appropriate assay. 
Repeated administration of bMCA did not affect levels of bMCA or re-
sult in a detectable anti-bMCA response (heifers 26 and 29; Table 1). It 
should be noted, however, that the detection limit of the anti-bMCA assay 
is 500 ng Ig/ml plasma, whereas the amount of anti-mMCA antibodies in mMCA-
treated heifer 13 was not more than 567 ng Ig/ml plasma. 
When bMCA or mMCA were simultaneously administered with an intramus-
cular injection of PMSG, a gradual increase in number of CL was observed 
in the mMCA plus PMSG injected animals (Table 1). The observed decrease 
in in vivo neutralizing capacity of mMCA is in agreement with the increased 
levels of circulating PMSG detected in the enzyme immunoassay (Fig. 2; 
Table 1). These findings correlate with the rapid clearance of the mMCA 
from circulation after the second and third injection (Table 1). This 
clearance may be caused by the with time increasing anti-mouse response 
which was largely anti-idiotypic in one of two heifers after the second 
injection (Figs. 4 and 5). When injected intramuscularly, PMSG reaches 
its maximum plasma concentration 12 to 24 h after injection (Menzer and 
Schams, 1979). Therefore, a considerable part of the intravenously admi-
nistered mMCA can be bound by anti-mMCA antibodies before it may form a 
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complex with PMSG. This may explain the temporary drop in anti-mMCA anti-
body levels (insert Fig. 5), that occurred immediately after the last 
treatment. 
The different reactions observed in the mMCA plus PMSG treated animals 
after the second injection (heifer 6: largely anti-idiotypic, increased 
PMSG levels and stimulated ovaries; heifer 2: anti-isotypic antibodies, 
baseline levels of PMSG and non-stimulated ovaries; Table 1) suggest that 
mMCA are hindered in their PMSG-neutralizing activity more by anti-idio-
typic than by anti-isotypic antibodies. When present in larger quantities, 
anti-isotypic antibodies can also prevent the neutralizing activity of 
mMCA, as is illustrated by the presence of high PMSG levels and an 
increased number of CL in both heifers after the third injection with mMCA 
plus PMSG, when anti-isotypic antibodies are dominantly present. This is 
not completely in line with the currently accepted idea that only anti-
idiotype antibodies can block monoclonal antibody functions (Chatenoud, 
1986). We cannot exclude, however, the possibility that there is a small 
anti-idiotypic component in the anti-mouse response that is below the "cut-
off" level in our assay. 
Typically, when mMCA were injected together with PMSG, a more dramatic 
humoral response against the mMCA was observed than when mMCA alone were 
administered (Table 1). A possible explanation for this phenomenon may 
be that, due to their larger molecular size, the PMSG - anti-PMSG immune 
complexes formed in vivo are more rapidly cleared from circulation than 
monomeric mouse IgG^. As a consequence, levels of processed immune complex-
es exposed on antigen-presenting cells exceed that of processed monomeric 
IgGi, the latter probably remaining below threshold levels necessary for 
triggering of an immune response. Moreover, it should be noted that both 
PMSG and mMCA are xenogeneic proteins. 
No increase in bMCA levels in plasma from bMCA plus PMSG-treated ani-
mals was found, except in heifer 28 after the second injection. This rise 
in the level of circulating bMCA coincides with a strong rise in PMSG le-
vels (Table 1). Although levels of bMCA remained low after injection of 
bMCA plus PMSG, no anti-bMCA antibodies could be detected. Several other 
types of assays were employed (e.g. an inhibition assay, Wissink et al., 
1989), but these also failed to detect anti-bMCA antibodies. These findings 
are in agreement with the observations that in the bMCA plus PMSG-treated 
heifers the PMSG plasma levels are in general very regular in height after 
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the successive injections and no clear relationship exists between the 
number of ovulations and the experimental periods (Table 1). 
Apparently bMCA were not able to prevent multiple ovulation in all 
cases. Although a direct relationship between bMCA and PMSG levels indi-
cates that binding of bMCA to PMSG occurs in vivo, PMSG levels in plasma 
from bMCA plus PMSG-treated animals were found to be slightly, but signi-
ficantly, increased to values in between the baseline levels obtained with 
mMCA plus PMSG-treated heifers and the much higher levels observed in a 
control animal injected with 3000 IU PMSG only (not shown). These data, 
together with the finding that bMCA levels did not rise after injection 
of animals with bMCA plus PMSG, may suggest that higher doses of bMCA have 
to be injected to neutralize PMSG activity in vivo. 
Data from an additional experiment indicate that bMCA in the dosages 
used only partially suppress multiple ovulation, i.e. partially neutralize 
the activity of PMSG in vivo (De Bruijn and Booman, 1989). In this expe-
riment two groups of 4 cows were injected on Day 11 ± 1 of the cycle with 
3000 IU PMSG in combination with either 1.4 or 2.1 mg bMCA, capable of 
neutralizing 6000 and 9000 IU PMSG in vitro, respectively. A control group 
of 15 cows was treated with PMSG only. The number of CL (means ± standard 
deviations) were 2.5 ± 1.5 and 5.0 ± 3.8 for the groups treated with 1.4 
and 2.1 mg bMCA, respectively, compared with 10.7 ± 2.1 for the control 
group. 
When the different PMSG-neutralizing capacities of mMCA and bMCA in 
vivo are taken into account, together with the possible differences in 
association constants of mMCA and bMCA for PMSG, the restricted number 
of animals tested and the limitations of the assays, one may conclude that 
the efficacy of the murine antibodies decreases due to the anti-mouse anti-
body response after repeated administration, whereas no such effect was 
found for the bovine antibodies. These results support the carrier-hapten 
effect hypothesis proposed by Ehrlich et al. (1987). Although our results 
indicate that in cattle homologous antibodies might offer advantages over 
their murine counterparts for repeated passive immunization, it has been 
shown that murine monoclonal antibodies can be succesfully applied in cat-
tle treated for superovulation (Dieleman et al., 1989). Moreover, in cows 
that were treated repeatedly for superovulation the efficacy of the murine 
antibody could be demonstrated (Gielen et al., 1989). We are currently 
extending our experiments to confirm the generality of our findings. 
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SUMMARY AND FINAL REMARKS 
One of the landmarks in immunology was the invention and development 
of monoclonal antibody-secreting hybridomas by Milstein and his coworkers. 
The enormous promise of monoclonal antibody technology, which became ap-
parent soon after its discovery, may explain the unusual speed with which 
monoclonal antibodies have been applied to biological and medical sciences. 
In animal production monoclonal antibodies are increasingly finding 
application in the areas of diagnostics, passive immunization and funda-
mental research. In Chapter 1 of this thesis some applications of mono-
clonal antibodies within these areas, with emphasis on reproduction, are 
discussed. It has been concluded that the particular advantages of monoclo-
nal antibodies can firstly and most easily be shown in immunodiagnosis. 
Once a hybridoma producing a monoclonal antibody appropriate for a parti-
cular application has been obtained, large amounts of a homogeneous and 
reliable reagent are available for as long as they are needed. As ingre-
dients in test kits, monoclonal antibodies have rapidly replaced conven-
tional polyclonal antibodies. 
An example of a typical diagnostic test in animal production in which 
monoclonal antibodies might be used is the milk-progesterone test for con-
firmation of oestrus and pregnancy diagnosis in cattle. In Chapter 2 the 
production and characterization of monoclonal antibodies against proges-
terone have been described in order to standardize an enzyme immunoassay 
for milk-progesterone. The antibodies differed considerably in their bind-
ing affinity for progesterone and showed distinct specificities for a va-
riety of steroids. Results show that, although the technique of monoclonal 
antibody production selects antibodies specific for a single antigenic 
determinant, this does not always preclude the possibility of cross-reacti-
vity. Moreover, most antibodies produced have affinities far below the 
corresponding conventional antisera, as has been discussed in Chapter 1. 
The monoclonal antibody with the highest association constant and rela-
tively good specificity did not detect progesterone with any greater sensi-
tivity than the conventional polyclonal sera. However, since monoclonal 
antibodies avoid the dependency upon animals producing high quality anti-
sera and improve test standardization, a commercially available rapid pro-
gesterone cow-side test has been designed based on the monoclonal anti-
body with the best characteristics. 
139 
Results of Chapter 2 underline the necessity to evaluate carefully the 
need of producing monoclonal instead of polyclonal antibodies for a given 
antigen, as considerable time and effort are required to obtain a monoclo-
nal antibody with suitable properties. Preselection of antibodies on affi-
nity and specificity in an early stage makes the monoclonal antibody tech-
nology more efficacious. In our laboratory a cocktail of related steroids 
was used to enable such an early selection of antibodies against either 
oestrone or oestrone sulphate. Testing the replacement of oestrone, coupled 
to horse-radish peroxidase, from the antibodies made it possible to produce 
high affinity monoclonal antibodies with nearly unique specificities in 
a relatively short time. Experiments are in progress to develop a test 
for pregnancy diagnosis in pigs in faecal samples based on those antibo-
dies . 
Another application in diagnostics is the use of monoclonal antibodies 
against a male-specific protein, the H-Y antigen, for sexing bovine em-
bryos before implantation. H-Y is a weak antigen and immunization with 
H-Y antigen in an inbred strain of mice usually results in production of 
low titered, low affinity antisera. Because only a low percentage of mice 
has a good antibody response and their sera run out quickly, monoclonal 
antibodies were produced (Chapter 3). Male specificity of the antibodies 
was tested in a variety of assays including enzyme immunoassays based on 
various sources of soluble H-Y and indirect immunofluorescence assays based 
on binding of the antibodies to H-Y antigen on the cell surface of male 
and female cells obtained from a number of tissues and species. Several 
monoclonal antibodies appeared to be positive in all assays tested, sug-
gesting that the molecule conferring the H-Y antigenicity lacks species-
specificity and appears to be identical for soluble and membrane-bound 
H-Y antigen. 
The most promising monoclonal antibodies reactive with the H-Y antigen 
have been evaluated for their efficiency in sexing Day 7 bovine preimplan-
tation embryos (Chapter 4). Although in an indirect immunofluorescence 
assay a discrimination between male and female embryos could be made, eva-
luation of the staining patterns was fairly subjective because of non-spe-
cific binding of the monoclonal antibodies to the embryonic cells. After 
modifying the technique in order to reduce non-specific binding, the number 
of false positives after sexing under these conditions was greatly reduced, 
which suggests that the monoclonal antibodies detect a male-specific anti-
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gen. It was concluded that the occurrence of false-negative embryos might 
be caused by a weak expression of the H-Y antigen and/or a low affinity 
of the monoclonal antibody for bovine cell-surface H-Y antigen. The anti-
bodies used in our experiments had been selected on basis of their binding 
to both soluble and cell-surface H-Y antigen originating from different 
sources. Currently, monoclonal antibodies which are selected on high affi-
nity for protein structural determinants on bovine cell-surface H-Y antigen 
are being produced in order to be used in a highly discriminating sensitive 
fluorescence assay. 
In Chapter 1 has been discussed that it will take some time to fully 
realize the potential of monoclonal antibodies in the area of passive immu-
nization or immunomodulation. The production costs are still relatively 
high and the reaction of the animal to the injected antibodies may limit 
the effects of passive immunization. Some such limitations are illustrated 
in the experiments in which anti-progesterone murine monoclonal antibodies 
were administered to cyclic pigs (Chapter 5). Intravenous injection of 
increasing amounts of anti-progesterone antibodies resulted in a concomi-
tant rise in levels of antibody-bound progesterone. At the same time a 
significant rise in plasma concentrations of total progesterone was obser-
ved immediately after administration of higher doses of antibodies. There-
fore, the net effect of progesterone binding by the antibody was relatively 
small and more or less independent of the quantities of antibody adminis-
tered. It has been suggested that animals maintain adequate levels of free 
progesterone in their circulation by resorption of progesterone from a 
pool present in body tissues. The effects of administration of anti-proges-
terone antibodies on plasma levels of free progesterone are, however, not 
only influenced by the proposed compensating effect of resorption, but 
also by the possible initiation of a humoral response of the pigs to the 
injected antibodies. In the experiments described in Chapter 5 it is shown 
that a minimum dose of 32 mg anti-progesterone antibody elicited an anti-
mouse response after the first injection, having an neutralizing effect 
on the anti-progesterone monoclonal antibodies administered with the second 
injection. When smaller quantities of antibody were used, an anti-mouse 
reaction was detected after the second or third injection. 
From reports concerning the therapeutic use of monoclonal antibodies 
in man it is known that such an immune response may be directed partially 
against the isotypic determinants, partially against the idiotypic deter-
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minants of the murine antibodies administered. Although anti-idiotypic 
responses cannot be excluded as a complicating factor, homologous anti-
bodies might offer some advantages over their murine counterparts in terms 
of effectiveness for passive immunization. 
In Chapter 6 the construction of a bovine-murine heteromyeloma cell 
line to be used for the production of bovine monoclonal antibodies has 
been described. It was anticipated that a heteromyeloma would retain the 
superior fusion characteristics of the mouse myeloma cells and, because 
of the presence of bovine chromosomes, would be better able to support 
stable bovine antibody production than interspecies hybridomas produced 
by fusing mouse myeloma cells with bovine lymphocytes. First (bovine-mu-
rine) and second generation (bovine-[bovine-murine]) fusion partners were 
compared for fusion efficiency and the generated number of antigen-specific 
antibody-producing clones. In addition, the optimal time-interval between 
boosting and harvesting of the lymphocytes for fusion and the source of 
lymphocytes was studied. It could be concluded that fusion of bovine lymph 
node cells with the second generation heteromyelomas on Day 7 after the 
final booster injection resulted in the largest number of specific anti-
body-producing clones. Experiments with a third generation bovine-murine 
heteromyeloma cell line indicated that fusion efficiency could be further 
improved (unpublished data). Studies with anti-rotavirus and anti-pregnant 
mare serum gonadotrophin (PMSG) bovine monoclonal antibodies, produced 
with the second generation fusion partners, indicate that the heteromyeloma 
cell lines are very useful for the production of bovine monoclonal anti-
bodies . 
The availability of such bovine monoclonal antibodies offers the pos-
sibility to compare the efficacy of homologous and heterologous antibodies 
in cattle after repeated passive immunization. The in vivo immunoneutrali-
zation of PMSG by murine and bovine monoclonal antibodies was chosen as 
a model for such a study (Chapter 7). Results indicate that repeated in-
jection of murine monoclonal antibodies against PMSG (mMCA) alone did not, 
or only to a small degree, elicit an anti-mouse immune response. The simul-
taneous administration of mMCA and PMSG resulted in relatively high levels 
of anti-mouse antibodies after the second injection, leading to a decrease 
in neutralizing activity of mMCA. The results suggest that the neutralizing 
activity of mMCA is inhibited more by anti-idiotypic than by anti-isotypic 
antibodies against mMCA. After repeated administration of the bovine mono-
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clonal antibody against PMSG (bMCA), either alone or in combination with 
PHSG, no anti-bMCA antibodies could be detected. In addition, no change 
in plasma levels of bMCA and PMSG, compared with levels after the first 
injection, was observed. Although it has to be confirmed by further experi-
ments whether our findings can be generalized, the present results suggest 
that for repeated passive immunization in cattle homologous antibodies 
are to be preferred above heterologous antibodies. As far as we can see 
now it is necessary to evaluate carefully the need to produce homologous 
or heterologous antibodies, dependent on the amounts of antibody to be 
administered and the number of treatments. 
In conclusion, the potential of monoclonal antibodies for diagnostic 
use, therapy or fundamental research, discussed in Chapter 1, together 
with the results presented in this thesis indicate that the monoclonal 
antibody technology will have an important impact on the improvement of 
animal quality and productivity. 
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POPULAIRE SAMENVATTING 
Sinds Köhler en Milstein ongeveer vijftien jaar geleden de hybridoma-
techniek ontwikkelden, waardoor het mogelijk werd monoclonale antistoffen 
met de grootst mogelijke specificiteit in vrijwel onbeperkte hoeveelheden 
te produceren, heeft de toepassing van deze techniek in het medisch-biolo-
gisch onderzoek een stormachtige ontwikkeling doorgemaakt. Monoclonale 
antistoffen zijn thans ook niet meer weg te denken uit het onderzoek in 
de dierlijke produktie. 
Belangrijke toepassingsgebieden van monoclonale antistoffen in de dier-
lijke produktie zijn de diagnostiek, de beïnvloeding van fysiologische 
processen door middel van passieve immunisatie en het fundamentele onder-
zoek. In Hoofdstuk 1 van dit proefschrift worden enkele toepassingen van 
monoclonale antistoffen op genoemde gebieden, met name op het terrein van 
de voortplanting, besproken. De voor- en nadelen van monoclonale antistof-
fen ten opzichte van polyclonale antisera, alsmede de beperkingen van de 
huidige techniek en de te voorziene verbeteringen dienaangaande in de ko-
mende jaren, worden uitvoerig beschreven. 
Als voorbeeld van het gebruik van monoclonale antistoffen in de diag-
nostiek wordt in Hoofdstuk 2 de produktie en karakterisering van monoclo-
nale antistoffen tegen progesteron beschreven voor toepassing in de melk-
progesterontest. Via bepaling van het progesterongehalte in de melk kan 
worden vastgesteld of een koe al dan niet tochtig of drachtig is. Hoewel 
de verkregen monoclonale antistoffen, wat specificiteit en affiniteit (= 
de mate van binding) voor progesteron betreft, niet beter waren dan een 
reeds beschikbaar polyclonaal antiserum, werd toch uit het oogpunt van 
standaardisatie op basis van een monoclonale antistof een "cow-side test" 
ontwikkeld. 
Een tweede voorbeeld van toepassing van monoclonale antistoffen in de 
diagnostiek betreft het bepalen van het geslacht van runderembryo's voor-
afgaand aan transplantatie, met behulp van antistoffen tegen het H-Y anti-
geen. Het H-Y antigeen is een anti-transplantatie antigeen dat op het op-
pervlakte-membraan van uitsluitend mannelijke cellen voorkomt. In Hoofdstuk 
3 is de produktie en karakterisering van monoclonale antistoffen tegen 
het H-Y antigeen beschreven. Enkele antistoffen werden verkregen die zowel 
een goede binding gaven met oplosbaar H-Y antigeen afkomstig van meerdere 
bronnen alsook met membraan-gebonden H-Y antigeen van verschillende typen 
cellen afkomstig van diverse diersoorten. 
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De daarvoor het meest in aanmerking komende monoclonale antistoffen 
tegen het H-Y antigeen zijn vervolgens toegepast in een indirecte fluo-
rescentietest voor het onderscheiden van het geslacht van runderembryo's 
(Hoofdstuk 4). De nauwkeurigheid van deze test bedroeg aanvankelijk 77%, 
waarbij zowel vals-positieve als vals-negatieve uitslagen voorkwamen. Na 
optimalisatie van de testcondities was de nauwkeurigheid lager, namelijk 
73%. Er kwamen echter geen vals-positieve uitslagen meer voor, wat betekent 
dat de antistoffen specifiek mannelijk zijn. 
In Hoofdstuk 5 is beschreven in hoeverre monoclonale antistoffen tegen 
progesteron gebruikt kunnen worden voor de beïnvloeding van fysiologische 
processen door middel van passieve immunisatie. Het bleek dat na toediening 
van verschillende hoeveelheden antistoffen aan cyclische gelten de plasma 
progesteron spiegels (d.w.z. het niet aan de antistoffen gebonden proges-
teron) slechts in zeer geringe mate en voor korte tijd gereduceerd waren. 
Zodra het progesteron in de bloedbaan aan de antistoffen wordt gebonden, 
komt mogelijk progesteron vrij dat in het vetweefsel in grote hoeveelheden 
is opgeslagen. De voor de weefsels beschikbare hoeveelheid progesteron 
blijft daardoor min of meer constant. Bij de experimenten kwam eveneens 
naar voren dat bij het varken na herhaald toedienen een immuunrespons wordt 
opgewekt tegen de monoclonale antistoffen. De monoclonale antistoffen zijn 
van muize-origine en het varken herkent deze als lichaamsvreemd. 
De anti-muis reaktie bij het varken was mede aanleiding om een systeem 
te construeren voor de produktie van voor landbouwhuisdieren homologe anti-
stoffen (Hoofdstuk 6). Door de muize myeloma cellen enkele keren te fuseren 
met lymfkliercellen van het rund, werd uiteindelijk een rund-muis hetero-
myeloma cellijn verkregen waarmee op relatief efficiënte wijze runder mono-
clonale antistoffen kunnen worden geproduceerd. In dit kader werd ook aan-
dacht besteed aan de geschiktheid van antigeen-gestimuleerde runder milt-
cellen ten opzichte van lymfkliercellen voor fusie met de heteromyeloma 
cellijn, alsmede aan het optimale tijdstip voor fusie na de laatste anti-
geen- stimulatie. Tijdens het gehele proces van ontwikkeling van de hetero-
myeloma cellijn zijn runder monoclonale antistoffen geproduceerd tegen 
rotavirus en pregnant mare serum gonadotrophine (PMSG). 
Doordat ook muize monoclonale antistoffen tegen PMSG commercieel ver-
krijgbaar zijn, kon tenslotte een vergelijkende studie verricht worden 
naar de geschiktheid van muize monoclonale antistoffen ten opzichte van 
runder monoclonale antistoffen voor neutralisatie van PMSG in vivo na her-
haalde toediening bij het rund (Hoofdstuk 7). Met name bij gelijktijdige 
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toediening van de muize monoclonale antistoffen en PMSG werden direkt na 
de 2e injectie en in nog sterkere mate na de 3e injectie anti-muis anti-
stoffen aangetoond. Tegelijkertijd nam de neutralisatie van PMSG door de 
muize monoclonale antistoffen af. Na herhaalde toediening van runder mono-
clonale antistoffen, al dan niet in combinatie met PMSG, konden geen anti-
stoffen gericht tegen de runder monclonalen worden aangetoond. Voorlopige 
resultaten wijzen er dan ook op dat bij herhaald toedienen van monoclonale 
antistoffen de voorkeur gegeven dient te worden aan homologe in plaats 
van heterologe antistoffen. 
Door het uitwerken van enkele typische voorbeelden van toepassingen 
van monoclonale antistoffen in de diagnostiek en door het onderzoek naar 
het effectief toepassen van monoclonale antistoffen in het kader van de 
beïnvloeding van fysiologische processen door middel van passieve immuni-
satie, alsmede door het bespreken van enkele voorbeelden van toepassingen 
in het fundamentele onderzoek, kan dit proefschrift bijdragen tot het ver-
krijgen van meer inzicht in de waarde van monoclonale antistoffen voor 
de dierlijke produktie. 
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